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Tumour debulking surgery aims to produce a smaller target for adjuvant therapy whilst 
also removing much of the tumour associated immunosuppression. Even so, cures are 
rarely seen in either animal studies or human patients receiving debulking surgery plus 
adjuvant chemo-immunotherapy, despite evidence of effector T cell activation that should 
be strong enough to overcome tumour growth. Adjuvant immunotherapies can be used to 
eradicate distant micro metastases or cancer cells that remain after surgery, but have 
limited success. This could be due to ‘immune brakes’ that continue to operate, 
suppressing the anti-tumour response. This is particularly true for mesothelioma, 
metastatic melanoma and colorectal cancer, which are the main focus of this project. 
Tumour-induced immune suppression may be caused by suppressive immune cells such as 
regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs). Both of these 
cellular populations suppress the anti-tumour effector T cell responses including the 
effectiveness of cytolytic CD8+ T cells both systemically and locally. This project will use 
a combined approach to alleviate immune suppression in combination with debulking 
surgery through the targeted removal of suppressive Treg and MDSC subsets. 
This project aimed to improve the response seen with debulking surgery by removing 
tumour-associated immune suppression. The hypothesis was that removing these ‘brakes’ 
on the anti-tumour immune response would release a stronger, lasting anti-tumour 
response elicited by adjuvant immunotherapy after surgical debulking. Thus, the results 
from this study may direct future clinical trials and potentially allow partial debulking 
surgery to remain a valid treatment option for these patients, especially if followed with the 
appropriate immunotherapy regimens. 
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Chapter 1: Literature Review 
 
1.1 Cancer 
Cancer has become one of the most varied and widespread diseases worldwide with a large 
proportion of the global population having encountered it either directly or indirectly. It 
occurs in numerous forms with a large variation in causes, pathogenesis and survival. In 
Australia, more than 43700 people died from cancer in 2011. Treatment for cancer also 
places a huge burden on the health system, costing approximately $3.8 billion or 7.2% of 
the health budget (Australian Institute of Health and Welfare, 2012). Cancer refers to a 
larger group of varying pathogenic conditions with the common factor being the malignant 
transformation of normal cells into oncogenic cells that can grow and proliferate 
uncontrollably. Currently there are more than 200 different types of cancer which can 
affect every organ of the human body with many of the cell types making up those organs 
susceptible to malignant transformation (Cancer Research UK, 2012) 
 
Predominantly, cancers present themselves as a solid malignancy in which a mass is made 
up of one or more oncogenic cell types that has entered a stage of uncontrolled 
proliferation that leads to the formation of a mass. This occurs as a result of the body’s 
immune system failing to recognise and respond to cells undergoing oncogenic 
transformation as a result of specific genetic mutations. The cause of these genetic 
alterations are largely environmental with exposure to certain mutagens as well as lifestyle 
choices such as dietary intake and alcohol consumption being responsible for 
tumourigenesis (Sankpal et al., 2012).  
 
Treatments for cancer are varied and include the use of cytotoxic chemotherapeutic agents, 
radiotherapy, surgery and immunotherapies with the goal of eliminating all traces of the 
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oncogenic cells while limiting side effects. A combination of these or a combination of 
different chemotherapy drugs is often used to achieve synergistic effects between 
individual treatments and has been shown to improve patient outcome especially with the 
formation of a solid tumour mass (Prados et al., 2012). These solid masses become 
incredibly resistant to current treatment options and as a result the first point of attack is 
often surgery with the aim to either completely remove the tumour or reduce its size and 
impact on the host and then treat with an adjuvant therapy to clear the remaining cells 
(Yano et al., 2009). The role of immunotherapies for use in the successful treatment of 
solid cancers has increased dramatically especially in those that are currently resistant to 
conventional cancer therapy regimes. Several solid cancers have shown a susceptibility to 
immunotherapeutic agents and include malignant mesothelioma (Bograd et al., 2011), 
metastatic melanoma (Wolchok et al., 2013) and colorectal carcinoma (Lin et al., 2013) 
and tumour models of these diseases were used in this study. 
 
1.2 Solid Malignancies 
In most cases, carcinogenesis results in the formation of a solid tumour of the tissue type in 
which the mutations have occurred. These may either be benign and therefore do not 
spread to other tissues or they may be metastatic where the primary tumour can invade 
surrounding tissue, enter the circulatory system and spread to other parts of the body.  
 
1.2.1 Malignant Mesothelioma 
Malignant mesothelioma is a highly treatment-resistant cancer that is increasing in 
frequency both in Australia and worldwide (Robinson, Musk, et al., 2005). Mesothelioma 
is a cancerous tumour that affects the serosal surfaces of the body, namely the pleura, 
peritoneum and pericardium and is named after its effect on the mesothelium membrane 
found lining these areas. This cancer is highly associated with asbestos exposure and its 
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widespread use during the 20th century due to its exceptional fire-resistant properties with 
its link to mesothelioma only being discovered in 1960 (Ismail-Khan et al., 2006). 
Detection of mesothelioma is often associated with the development of a pleural effusion 
and associated chest pain and the median survival for someone diagnosed is 9 to 12 months 
with a very small number of patients surviving past that. The vast majority of patients 
affected by mesothelioma are male.  
 
Treatment of mesothelioma depends on the staging of the disease and is mostly palliative 
due to the cancer not responding well to current treatment protocols. This may involve 
surgery for either diagnostic, palliative or on rare occasions, the potential cure of the 
disease (Robinson & Lake, 2005). The goal of surgery in mesothelioma is to perform 
cytoreductive or debulking surgery to remove all macroscopic evidence of the cancer and 
then treat with adjuvant therapies (Remon et al., 2013). This is mainly due to the diffuse 
nature of the cancer with aggressive surgical approaches resulting in the patient being 
placed under a huge amount of stress. Patients are often excluded from debulking surgery 
of mesothelioma for various reasons ranging from the extent of the disease and their 
willingness to receive adjuvant therapy to their general health and wellbeing (Yano et al., 
2009). 
 
Chemotherapy is the primary adjuvant therapy option but is not extensively effective and is 
often used as a palliative approach (Sterman et al., 2005). Chemotherapeutic agents used 
for the treatment of mesothelioma work more effectively when used in combination with 
the platinum-containing drugs that have a higher activity than those that do not. The most 
effective of these are cisplatin and doxorubicin with a response rate of 28.5% versus 11.3% 
for a single therapy. An exception to this was the response rate of treatment with an 
antifolate drug methotrexate in which a cohort of patients were treated with a high dose 
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that resulted in a response rate of 37% compared to 32% showing no change and the 
remainder having progressive disease (Remon et al., 2013). Other chemotherapy agents in 
use include cisplatin, raltitrexed and gemcitabine although all of these have response rates 
below 30% and survival rates often less than 1 year (Lee et al., 2009). 
 
The urgent need for more effective treatment therapies for mesothelioma has prompted 
researchers to develop treatments that reduce both the incidence and severity of this fatal 
disease. For this reason the opportunity exists for an immunotherapy to be developed to 
cause the body’s immune system to attack and potentially destroy the cancerous cells. As a 
surgical approach to mesothelioma cannot remove the entire tumour as some areas are hard 
to access or diffuse microscopic cancerous deposits are present (Sterman et al., 2005), an 
immunotherapy designed to attack these remaining cells may prove effective in increasing 
both patient quality of life and long term survival.  
 
1.2.2 Metastatic Melanoma 
Melanoma is a malignant cancer of melanocytes, the cells responsible for the production of 
the pigment melanin. In Australia, it is the third most common cancer in both men and 
women and while it makes up only 2.3% of all skin cancers it is responsible for 75% of 
skin cancer related deaths. When the disease is diagnosed early, the tumour can be 
removed with little risk however at later stages the prognosis is very poor with a median 
survival of 6 to 10 months (Read, 2013). The primary cause of melanoma is exposure to 
ultraviolet (UV) radiation, in particular UV-B that can lead to burns, increased photo 
ageing of the skin and skin carcinogenesis (Elmageed et al., 2009). Diagnosis of 
melanomas are usually done visually by identifying moles that may have an irregular shape 
or colour and a diameter larger than 6 mm and still growing, as well as with a skin biopsy. 
The confirmation of metastatic melanomas involves diagnostic scanning to detect 
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metastases with positron emission tomography and computed tomography (PET/CT) 
rapidly becoming the most accurate diagnostic method. It is also as able to detect a 
potential response to treatment by measuring changes in the size of metastatic tumours 
(Read, 2013).  
 
Treatment for non-metastatic melanoma involves surgical resection of the tumour that is 
often curative with adequate excision margins to ensure the entire mass is removed. A 
melanoma that has metastasised is much harder to treat and requires the use of adjuvant 
therapies such as combination chemo-immunotherapy using the chemotherapy agent 
dacarbazine and the immunotherapy interlukin-2 (IL-2) although this combination has a 
relatively low response rate between 10-20% (Spagnolo et al., 2012). As melanoma can be 
quite an immunogenic cancer as a result of detectable tumour-associated antigens (TAA) 
such as MAGE-1, CDK4 and TYRP1, the possibility of a successful immunotherapy 
regime looks promising (Gyorki et al., 2013). The latest advances in melanoma 
immunotherapy are focused on blocking inhibitory molecules such as cytotoxic T-
lymphocytes antigen 4 (CTLA-4) and programmed death protein-1 (PD-1) with humanised 
antibodies already developed against these targets termed Ipilimumab and Nivolumab 
respectively (Wolchok et al., 2013). Both of these molecules have roles in limiting T cell 
function and blocking them allows T lymphocytes to remain functional for longer. A 
recent clinical trial combining both therapies showed that at the maximum doses, 53% of 
patients had an objective-response with all having a minimum of 80% reduction of tumour 
mass (Wolchok et al., 2013). This demonstrates a clear link between metastatic melanoma 






1.2.3 Colorectal Carcinoma 
Colorectal cancer is one of the more common cancers. It results from uncontrolled cellular 
growth in the colon and rectum with roughly 9.7% of all cancers being in the colon 
(Harrison et al., 2011). This cancer has a number of risk factors associated with its 
development such as increasing age, male gender and environmental factors including poor 
diet and smoking. Roughly two-thirds of the incidence of colorectal cancer can be 
attributed to inflammatory bowel disease with risk increasing the longer the disease exists 
as well as the severity of the inflammation. Diagnosis of this cancer is accomplished via a 
colonoscopy or sigmoidoscopy as well as a tumour biopsy. A CT scan is often done to 
detect or rule out metastasis (Cunningham et al., 2010).  
 
The treatment of colorectal cancer primarily involves resection of the tumour with the hope 
that it can be entirely removed with adequate surgical margins. Removal of the lymph 
nodes aids in the staging of the disease and a higher number of positive nodes removed 
correlates with a higher patient survival (Le Voyer, 2003). For treatment of metastatic 
colorectal cancer, adjuvant therapies are used in combination with surgery and mostly 
include chemotherapy. The most common chemotherapy regime used for this cancer 
involves 5-fluorouracil (5-FU) in combination with leucovorin (LV) and has been 
associated with increased survival in patients with stage III disease (Carrato, 2008). 
Another common chemotherapeutic agent is capecitabine, an oral fluorouracil prodrug that 
is used to restrict the action of 5-FU to the site of the tumour, as capecitabine is converted 
to 5-FU by the high abundance of the enzyme thymidine phosphorylase (TP) at the tumour 
site within the colon (Carrato, 2008). Radiotherapy for colorectal cancer is not 
recommended as the bowels are highly sensitive to radiation but is used for the closely 
related rectal cancer (Cunningham et al., 2010).  With the lack of adjuvant therapies for 
colorectal cancer and with surgery the best hope of a cure, the opportunity again exists for 
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an immunotherapy regime to be developed to eradicate any metastatic disease that remains 
after surgical resection of the primary tumour mass. 
 
With conventional adjuvant therapies to surgery such as chemotherapy and radiation not 
being able to sufficiently provide curative options for these cancers, there is the potential to 
develop effective immunotherapies to induce an immune response to these solid 
malignancies. As surgery itself can remove a large portion of the tumour thereby reducing 
its burden on the patient, therapies to either boost an immune response or to remove 
tumour-associated suppression can promote eradication of any micro metastasis or 
unresectable tumour left behind after surgery. 
 
1.3 The Role of the Immune System in Cancer 
The immune system can detect and eliminate infectious organisms. To be able to use it to 
combat cancer in a similar way as other therapies, a solid understanding of the tumour 
immune response is needed to identify key points that can be targeted to either increase the 
response or remove suppression associated with the presence of a solid tumour. The 
majority of research into the role of the immune system within the cancer environment 
focuses on the adaptive response and how cytotoxic T lymphocytes (CTLs) are able to 
respond to a solid tumour. Evidence also suggests an important role of the innate immune 
system as well (Liu et al., 2012)  
 
1.3.1 The Immune System 
Our immune system plays a vital role in protecting us from infectious organisms as well as 
initiating the inflammatory response to remove the source of damage and repair that has 
already occurred. It needs to be able to correctly distinguish a pathogen, such as a virus, 
from self-antigens to ensure only harmful, foreign molecules are targeted. The immune 
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system can be separated into the innate and adaptive response with each containing a set of 
effector cells (Figure 1) that work together to drive the responses to foreign antigens 
(Dranoff, 2004). 
 
Figure 1: Innate and Adaptive Immunity (Dranoff, 2004) 
 
1.3.1.1 Innate Immunity 
The innate immune system is responsible for the fast, non-specific response to a foreign 
antigen. It has a very short lag time between exposure and response and it does not form 
immunological memory of encountered pathogens. This system is made up of cellular 
components such as granulocytes, mast cells, macrophages, dendritic cells (DCs) and 
natural killer (NK) cells which are the first line effectors in the anti-tumour immune 
response (Liu et al., 2012). Their response involves the recognition of foreign 
organisms/antigens and the orchestration of an inflammatory response towards them. 
Inflammation is mainly initiated by macrophages and DCs when they recognise pattern-
associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) 
and in response secrete inflammatory mediators that lead to the onset of inflammation 
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(Janeway, 2001). The innate system also includes soluble factors such as the complement 
system and is the major humoral component of the innate response. It functions by either 
binding complement proteins to antibodies already bound to TAAs/microbes or by direct 
binding that leads to a rapid immune response (Rus et al., 2005). Another feature of the 
innate immune system that is more relevant to infectious organisms are the barriers such as 
the skin and gastrointestinal tract. These act to prevent organisms entering the system 
including oncogenic viruses and contains additional defence mechanisms such as sweat, 
gastric acid and saliva (Janeway, 2001).  
 
1.3.1.2 Adaptive Immunity 
In contrast, the adaptive immune response is antigen-specific and is able to produce 
memory cells that can be initiated faster responses should that antigen be encountered 
again. This response is slower than the innate system due to the required expansion of 
lymphocyte populations. The cells that make up the adaptive immune system include 
B-lymphocytes that are responsible for antibody production and T-lymphocytes that are 
involved in the cell-mediated immune response (Dranoff, 2004). The antigen specificity is 
achieved by the somatic rearrangement of the antigen receptor genes responsible for the 
production of immunoglobulins for B-lymphocytes and the T cell receptors (TCR) for 
T-lymphocytes (Narendra et al., 2013). Once these antigen-specific receptors have been 
produced and activated and the pathogen has been cleared, there exists both memory B 
cells and memory T cells that retain those receptors and can recognise that same antigen if 
it is encountered in the future. This forms the basis of vaccination (Niederkorn, 2009).  
 
A key feature of the adaptive immune system is that it differentiates between self and 
non-self antigens. This allows the adaptive response to only initiate an immune response to 
antigens that are foreign such as a virus or to a lesser extent a tumour. When this process 
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fails it can result in non-specific recognition of antigens that may be classed as 
self-antigens which can then lead to the onset of autoimmune disease (Narendra et al., 
2013). This recognition of antigens is accomplished either directly by B-lymphocytes or 
via a process called antigen presentation for T-lymphocytes that allows them to mount an 
antigen-specific response against specifically-targeted cells. 
 
1.3.1.3 Antigen Presentation 
For the immune system to be able to recognise and respond to non-self antigens, they must 
be presented to T-lymphocytes via antigen presentation. This is done by antigen presenting 
cells (APC) such as DCs and macrophages as well as most host cells in terms of cytosolic 
antigens that bind antigens to the major histocompatibility complex (MHC). The MHC 
molecule consists of 2 classes, namely class I and class II. In normal antigen presentation, 
intracellular antigens are broken down into small peptides and loaded onto the MHC Class 
I molecule on the endoplasmic reticulum (ER) and presented to CD8+ CTLs. Extracellular 
antigens are captured and processed by APCs such as the DCs and loaded onto MHC class 
II molecules and presented to CD4+ helper T cells (Savina et al., 2007). There is an 
exception to this process in that antigens acquired exogenously such as those from a 
tumour can be presented via Class I to CTLs in a process called cross-presentation (Heath 
et al., 2004). This process is very important for both anti-viral and anti-tumour immune 
responses and allows for the induction of central and peripheral tolerance. This process is 
under very tight control as the activation of CTLs to infection or tumour antigens may lead 
to autoimmunity and non-specific responses of these CTLs (Flinsenberg et al., 2011). 
Knowledge of the role of DCs in cross-presentation is continuously expanding with 
research into this area focusing on the development of therapies to allow cross-presentation 
to be more effective. To do this requires adequate mouse models that lack 
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cross-presentation ability while not affecting the other functions of APCs involved in this 
process (Joffre et al., 2012). 
 
1.3.2 The Tumour Immune Response 
The onset of cancer is partly due to the fact that the immune system fails to recognise the 
oncogenic transformation and is unable to respond and eliminate those proliferating cells 
before a solid tumour has formed (Whiteside, 2006). To be able to identify therapeutic 
targets for novel immunotherapies, the immune systems control mechanisms for 




Burnet and Thomas introduced the theory of immunosurveillance in 1957 (Dunn et al., 
2002). The fundamental aspect of this was that the immune system, particularly 
lymphocytes, are able to patrol around the body and identify neoplastic cells and 
subsequently eliminate them. This theory has been supported by a number of experimental 
results showing that transplanted tumours were rejected when implanted into mice (Dunn 
et al., 2002). The presence of tumour infiltrating lymphocytes (TILs) is further evidence 
that the immune system can recognise and attack cancer cells (Kim et al., 2007). Despite 
evidence to suggest that this process is capable of preventing tumour growth, solid 
malignancies still do occur and therefore a new concept was introduced called 








This new concept proposed that cancer might edit a person’s immune system as to enable 
escape from immune responses. Immunoediting can be divided into 3 stages: elimination, 
equilibrium and escape. 
 
1.3.2.2.1 Elimination 
This stage involves both innate and adaptive immune responses to the tumour cells. 
Inflammation is then activated which leads to further recruitment of immune cells to the 
site of the cancer. Cells such as NK cells are stimulated to produce interferon gamma 
(IFN-γ) that can result in limited cancer cell death. The tumour antigens are collected by 
DCs that track to the lymph nodes that initiated the development of CTLs. These then enter 
the tumour site and attempt to bind with and eliminate the tumour cells expressing that 
antigen (Kim et al., 2007).  
 
1.3.2.2.2 Equilibrium and Escape 
Often some tumour cells are able to survive the elimination stage and enter equilibrium 
where tumour growth equals tumour death. Eventually, genetic mutations can lead to more 
of these tumour cells becoming resistant to the elimination processes such as IFN-γ and 
therefore enter the escape stage in which tumour growth proceeds and solid malignancies 
form while TILs are still present in the tumour (Vesely et al., 2013). 
 
1.3.3.1 The CTL Response to Tumours 
During the elimination phase, there is a response by CTLs, also know as CD8+ T cells. The 
response of these cells can be outlined in 6 main steps. The tumour immune response 
(Figure 2) begins with the detection of tumour antigens. These tumour-associated antigens 
(TAA) (step A) are detected within the tumour microenvironment as well as in the 
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periphery. They need to reach and be recognised by specialized APCs in the lymph nodes 
(step B) and presented on the MHC class I molecule to specific CD8+ T cells (step C). 
These CTL’s now proliferate and are programmed to recognise that TAA and enter the 
systemic circulation (step D) and traffic around the body. Some will enter the tumour 
blood vessel and pass into the tumour microenvironment where they can recognise the 
TAA they are specific for and exert their cytotoxic effect (step E). There is also the 
production of memory T-cells that will stay in the body and will be able to mount a rapid 
response should that specific antigen be encountered again, with production of both CD4+ 
and CD8+ cells (step F).  
 
Figure 2: Phases of an Effective CD8+ T-cell Response to a Solid Tumour(Lake et al., 2005) 
These CD8+ T cells should preferentially be capable of secreting IFN-γ and tumour 
necrosis factor-alpha (TNF-α) in order to directly lyse tumour cells (Lake et al., 2005). 
This response is not perfect and is often inhibited by suppression associated with both the 
presence of the tumour as well as by the recruitment of immune suppressive cells.  
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1.3.3.2 Immune Suppression in Cancer 
Once the CTL’s enter the tumour, they are exposed to suppressive cytokines produced by 
the tumour itself such as transforming growth factor-beta (TGF-β), Interleukin-10 (IL-10) 
and vascular endothelial growth factor (VEGF) (Nowak et al., 2006).  
The presence of a solid tumour also exerts a systemic suppressive effect on the immune 
system by a variety of mechanisms (Figure 3).  
Figure 3: Tumour Suppressive Effects on the Immune System (Evans et al., 2006) 
 
Tumours secrete immune mediators such as IL-10 and TGF-β that are able to reduce the 
function and number of key immune cells such as CTLs, DCs and NK cells while 
increasing the presence of Tregs (Evans et al., 2006). 
 
The immune mediator TGF-β inhibits perforin and granzyme mRNA expression that 
prevents lymphocyte proliferation. IL-10 inhibits the production of cytokines used by 
CTLs to kill cancer cells such as IFN-γ and TNF-α (Whiteside, 2006). The function, 
proliferation and maturation of CD8+ T-cells is suppressed which leads to an increase in 
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their apoptosis, corresponding with a blockade of step C in the tumour immune response. 
There is also a decrease in the numbers of DCs that leads to less antigen cross-presentation 
taking place that inhibits this stage of the tumour immune response (Flinsenberg et al., 
2011).  
 
The tumour cells are also able to create a shift from Th1 CD4+ T-cells that are able to 
activate cytotoxic T-cells, natural killer (NK) cells, macrophages and monocytes that 
would aid in attack of cancer cells to Th2 CD4+ T-cells. These Th2 cells prevent tumour 
rejection and many malignant cancers are associated with suppression of the Th1 response. 
Finally the cytokines, especially TGF-β, causes an increase in regulatory T cells (Treg) 
numbers both in the periphery and within lymphoid organs (Evans et al., 2006). Cellular 
suppression of the immune system can be accomplished by a number of cells with two of 
the most potent being Tregs and myeloid derived suppressor cells (MDSC). 
 
1.3.3.2.1 Regulatory T Cells 
Tregs are a subset of CD4+ T-cells with their main function being regulation or 
suppression of the immune system to prevent excessive responses. These functions include 
prevention of autoimmune disease, suppression of allergies and asthma, induction of 
tolerance and suppression of pathogen-induced immunopathology (Corthay, 2009). They 
develop from naïve T cells after exposure to TGF-β or are produced naturally in the 
thymus and then released into the periphery as a naturally derived Treg (Taams et al., 
2006).  
 
To identify these cells, several markers have been suggested and include CD25, CTLA-4 
and LAG-3. However there is growing evidence that these are not Treg specific, as CD25 
is expressed on activated T-cells and CTLA-4 is up regulated on all CD4+ and CD8+ cells. 
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This means another, more specific marker was required to ensure correct characterisation 
and study of this cellular subset. Forkhead box P3 (FoxP3) is a transcription factor 
involved in the development and production of Tregs and is generally used as a marker for 
these cells when doing pre-clinical in vivo work. In humans there is some evidence that 
FoxP3 is not exclusive to Tregs and may be transiently expressed by activated CD4+ and 
CD8+ cells although to a lesser extent than CD25 (Corthay, 2009). The role of Tregs in 
disease is clearly apparent with many studies looking at their mode of action in 
autoimmune diseases, allergic disease, infections and of course, cancer (Lin et al., 2013). 
High numbers of Tregs have been found in patients with lung, pancreatic, breast, liver and 
skin cancers and in many cases correlates with a decreased survival rate (Wolf et al., 
2003). The mode of action of Tregs is complex with a number of mechanisms used to 
achieve their regulatory or suppressive effects (Figure 4). 
 
Firstly, they are able to suppress the immune system by the release of inhibitory cytokines 
such as TGF-β, IL-10 and Interlukin-35 (IL-35). It has been well documented that these 
cytokines have a suppressive nature as well as having a role in the generation of Tregs 
(Chen et al., 2003). Cytolysis via the secretion of granzyme A or B is a mechanism used 
by NK cells and CTLs however Treg cells in humans have been shown to express 
granzyme A while in mice, granzyme B appears to be up regulated in Tregs. Other 
proposed mechanisms employed by Tregs include metabolic disruption where they 
consume local cytokines such as IL-2 leaving other cellular populations deprived and they 
eventually die. There is much debate around this mechanism and more work is needed 
before it can be regarded as a true ability of Tregs. Lastly, Tregs can target DCs that 
ultimately affect T-cell activation by inhibiting the maturation of these APCs. Again, there 
is little data showing this mechanisms in action and so further research is required to 























Figure 4: Regulatory T Cell Modes of Action (Vignali et al., 2008) 
 
1.3.3.2.2 Myeloid Derived Suppressor Cells 
Immune suppression can also be caused by the presence of myeloid derived suppressor 
cells (MDSCs). These are a heterogeneous population of immature myeloid cells (IMCs) 
that consist of the precursors to macrophages, DCs and granulocytes and expand during 
pathological conditions including cancer. They are mostly found in the bone marrow, 
making up 20-30% of the cell population in mice. A smaller proportion is found in the 
spleen and blood, roughly 2-4%. In mice they are characterised by the expression of Gr-1 
and CD11b (Gabrilovich et al., 2009). Their suppressive capacity is due to the production 
of immunosuppressive factors including arginase-1, inducible nitric oxide synthase (iNOS) 
and reactive oxygen species (ROS). MDSCs are consistently found within most cancers 
and can be increased up to 10-fold in patients that indicate a major role in immune 





1.3.3.2.3 Cancer Specific Immune Suppression 
This tumour-associated suppression is evident in the 3 cancer types specific to this study, 
(mesothelioma, melanoma and colorectal carcinoma). There is also the presence of an 
anti-tumour immune response that is not effective enough to deal with the solid 
malignancy (Bograd et al., 2011). Mesothelioma was once considered non-immunogenic 
but now it is accepted that this is not the case as infiltrating CD4+, CD8+ and Tregs have 
been found in mesothelioma biopsies (Hegmans et al., 2006). As it has been shown that 
mesothelioma patients who have an increased tumour-infiltrating CD8+ T cell response 
survive longer (Anraku et al., 2008), effective therapies to promote TIL recruitment are 
required. However, Tregs also infiltrate the mesothelioma tumour microenvironment and 
dampen the anti-tumour response helping to promote tumour progression. Targeting 
immune suppressors either systemically in the case of this study or possibly locally by 
intratumoural depletion may result in an effective CTL response within the tumour and 
lead to regression (Hegmans et al., 2006).  
 
The same principles apply to melanoma as it has been demonstrated that patients with 
stage IV melanoma had a significantly shorter survival rate when there was a higher 
proportion of Tregs present. The anti-tumour response being suppressed was the primary 
factor at work (Baumgartner et al., 2009). While melanoma is usually MHC Class I 
deficient and therefore poorly immunogenic, there are known melanoma antigens that can 
be recognised by the immune system. Therefore it is paramount that for the tumour to 
progress there needs to be suppression of effector and cytotoxic T lymphocytes and again 
Tregs are one of the primary cell populations that accomplish this. There are already Treg 
targeting immunotherapies for melanoma but these are not yet effective enough to bring 




The role of Tregs in colorectal cancer is slightly different. Suppressive Tregs increase with 
advancing stages of colorectal cancer and depletion of these would provide an effective 
strategy for treatment (Lin et al., 2013). There also appears to be a correlation between a 
high density of Tregs intratumourally and longer survival in patients which is contrasted 
against the majority of other solid cancers (Salama et al., 2009). An explanation of this is 
that the Tregs may in fact be dampening tumour development by suppression of the 
proinflammatory cytokine Th17 which is thought to promote tumour growth and Tregs 
may be capable of this due to adaptation to the tumour environment (Savage et al., 2013). 
Therefore it needs to be determined if removal of Tregs and subsequent removal of this 
proinflammatory suppression results in a CTL response that is more beneficial to the 
patient than if Tregs were not targeted.  
 
The role of MDSCs has been implicated in all 3 of these cancers types. These cells 
negatively regulate the immune response and thereby promote tumour growth. 
(Gabrilovich et al., 2009). Research has looked at both the correct characterisation of these 
cells as well as potential targeting agents to either remove or force the differentiation of 
these immature cells into their respective cell types. Treatments used include the anti-Gr-1 
antibody for removal of MDSCs in lung cancers represented in mice (Srivastava et al., 
2012) and the promotion of differentiation in colorectal cancer by the use of all-trans 
retinoic acid (ATRA) (Nefedova et al., 2007). The presence of MDSCs is also implicated 
in melanoma with the use of a PDE-5 inhibitor that suppresses the function of MDSCs and 
decreases their levels (Umansky et al., 2012). 
 
These 3 suppressive actions, the tumour itself, Tregs and MDSCs present areas in which 
targeted therapy can act. Possible therapies could focus on inhibiting the suppressive 
cytokines released by solid tumours in a targeted way as to not cause a systemic effect but 
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focus the CTL response only to the tumour. Removal of Tregs may also lead to a novel 
immunotherapy for cancers such as mesothelioma in which other, classical treatments are 
not effective. The immune response is already used for the defense against viral pathogens 
via the use of vaccines and so does present an opportunity to translate this to cancer 
immunotherapy, as this has already been done with the cervical cancer vaccine Gardasil. 
The role of MDSCs is constantly evolving with better characterisation and targeting 
therapies required to allow an effective immune response against solid tumours to 
progress. A further promoter of an immune response, as well as removing some of the 
tumour-associated immune suppression, is partial debulking surgery and this may be used 
in combination with an immunotherapy to promote tumour regression. 
 
1.4 Partial Debulking Surgery and the Immune Response 
Surgery is one of the primary treatments for solid cancers with the ultimate goal of 
removing the entire tumour mass. This however is not always possible and certainly with 
the 3 cancer types mentioned, complete resection is near impossible. This does however 
allow for the remaining tumour antigens to be used in the administration of 
immunotherapies which could possible have their effect enhanced by the remaining tumour 
cells. 
 
Surgical trauma often induces an acute response in patients that can cause cell-mediated 
immune suppression when there is a release of tumour cells into the system. There is also a 
risk of disseminated disease as a result of this and the extent of either outcomes has been 
correlated with the magnitude of surgical trauma (Evans et al., 2009). While this might 
prove contradictory to the use of immunotherapies, the removal of this suppression will 
allow an immune response to focus on smaller, more vulnerable tumour cells that have not 
yet re-established themselves. It has also been shown that newly developed surgical 
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techniques such as video-assisted thoracic surgery (VATS) has a number of benefits that 
include reduced recovery time, reduced pain and more importantly to the use of 
immunotherapies, a reduced extent of immune suppression that returns to normal more 
quickly than if major surgical techniques are used (Mohiuddin et al., 2013) 
 
1.5 Conclusion 
It is well established that the immune system plays a vital role in protection from cancer 
and is largely suppressed by the presence of a solid tumour. Existing adjuvant therapies to 
surgery may improve survival in some of the more fatal cancers but a curative option is not 
yet available for those such as malignant mesothelioma and metastatic melanoma. Surgery 
often leaves a portion of these cancer cells behind that subsequently grow and become 
more aggressive. The opportunity for the development of novel immunotherapies for these 
cancers is great with pre-clinical studies in mice showing promising results. While surgery 
seeks to target the primary tumour mass, the removal of tumour associated immune 
suppression such as Tregs or MDSCs will essentially remove the ‘brakes’ that are in place. 
This will allow an effective immune response to act upon the tumour or by combining it 
with another therapy that drives a response. This will hopefully result in a greater survival 
benefit from treatment and potentially offer a curative option for many fatal cancers. 
 
1.6 Project Hypothesis and Aims 
The hypothesis for this study is that targeting immune suppression via removal of Tregs 
and MDSCs will improve the post-surgical outcome of solid malignancies. 
 
The first aim of this project was to characterise the growth kinetics of the tumour models 
of mesothelioma, melanoma and colorectal cancer in mice and then develop protocols for 
partial debulking surgery in these. The second aim was to then use these surgery models in 
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combination with Treg depletion to determine its effect as well as what time this depletion 
should occur with reference to tumour size and day of surgery. A trial depletion of MDSCs 
will be done to determine if this is possible and potentially combine this with surgery. 
Finally, the last aim was to use the FoxP3.dtr model to characterise the effect of Treg 
depletion in the lymphoid organs and tumour to gain a better understanding of the systemic 
CTL response.  
 
1.7 Significance of This Study 
With treatment options for late stage mesothelioma, melanoma and colorectal cancer 
having a low survival and response rate, new treatments need to be investigated. As 
surgery is a primary treatment option for many cancers, this will be investigated by 
performing partial debulking surgery in combination with Treg/MDSC depletion 
immunotherapy with the aim of promoting an immune response capable of successfully 
eradicating the remaining tumour mass as well as inducing long-term immunological 
memory. The outcomes of this work showed that surgery in combination with Treg 
removal is capable of significantly increasing the survival rate of mice that had established 
tumours when compared to either treatment used alone. It also showed that Treg depletion 
can be a highly successful treatment option if their transient depletion can be accomplished 










Chapter 2: Materials and Methods 
 
2.1 Mice 
The mice used in this study included the BALB/c and C57BL/6J strains obtained from the 
Animal Resource Centre (Murdoch, Western Australia) and the BALB/c.Foxp3.dtr.Crslc 
(referred to as FoxP3.dtr) strain kindly provided by Prof. Ian van Driel (University of 
Melbourne, VIC). All were housed in pathogen free conditions at the UWA animal house 
located in M block, QEII Medical Centre. Predominantly, female mice aged between 6-8 
weeks were used for the BALB/c and C57BL/6J strains however due to availability, male 
mice were also used for the FoxP3.dtr strain with ages varying from 6 to 19 weeks. Any 
procedures and treatments as well as monitoring were approved by the UWA animal ethics 
committee and were conducted in accordance with the Australian code of practice for the 
care and use of animals for scientific purposes, 8th edition 2013 developed, by the National 
Health and Medical Research Council. 
 
2.2 Cell Lines 
The AB1-HA cell line was obtained from the National Centre for Asbestos Related 
Diseases. AB1-HA is a mesothelioma cell line established from in vitro culture of ascetic 
fluid taken from asbestos exposed BALB/c mice. The resultant AB1 cell line was then 
transfected with the influenza virus (PR8/34/H1N1 Mt Siani) haemagglutinin gene (HA) to 
provide a marker antigen and produce the AB1-HA line (Marzo et al., 1999). B16-F10 was 
obtained from the American Type Culture Collection (ATCC) and is a C57BL/6J mouse 
melanoma cell line. The BALB/c colorectal cancer cell line CT44, kindly provided by 
Prof. Kashayarsha Khazaie (Northwestern University, Chicago IL) was generated by 
transfecting the wild type CT26 cell line with a fusion protein of the HA and enhanced 
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green fluorescent protein (EGFP) (Khazaie et al., 2006). All cell lines were expanded in 
culture and frozen down and stored in liquid nitrogen for use in all experiments. 
 
2.3 Cell Culture 
The AB1-HA and B16-F10 cell lines were cultured in R10 media (Gibco® RPMI 1640 
Cell Culture Media containing L-glutamine with the addition of 0.02M Gibco® Hepes, 
0.12 U/mL Benzylpenecillin, 50 µg/mL gentamicin, 5x10-5M 2ME and 10% Foetal Calf 
Serum (FCS) v/v). R2 media, used for tumour digestion, contains the same supplements as 
R10 but instead with only 2% FCS v/v. For AB1-HA only, the media was also 
supplemented with 0.4 mg/mL of Geneticin. For maintenance of the CT44 cell line, 
DMEM complete media (Gibco® DMEM media supplemented with 0.02M Gibco® 
Hepes, 0.12 U/mL Benzylpenecillin, 50 µg/mL gentamicin, 5x10-5M 2ME, 10% FCS v/v 
and 1x Glutamax (diluted 1:100 v/v with DMEM media)) was used.  
 
To passage cells, all culture media from the flasks would be removed first by suction and 
then washed with 1x Phosphate Buffer Saline (PBS) to remove any remaining media. For 
AB1-HA and B16-F10 cell lines, 0.12% trypsin (Sigma-Aldrich, Castle Hill, NSW) was 
added to the flasks for 1-2 minutes to remove adherent cells while Cellstripper (Cellgro, 
Manassas, VA) was used for the CT44 cell line and left for 10 minutes at 37oC to remove 
cells. Once detached, washing flasks with 10 mL of their respective media then inactivates 
the trypsin or Cellstripper. These cell suspensions were collected into falcon tubes and 
spun down at 348 g for 3 minutes and the supernatant removed. Cells were then 
resuspended in a know volume of their media and split accordingly into new culture flasks. 
For maintenance of cell culture cells were split when between 80-90% confluency with 




2.4 Tumour Inoculations 
AB1-HA and CT44 were inoculated either into BALB/c or FoxP3.dtr mice while B16-F10 
was inoculated into C57Bl/6J mice. Firstly, cells were grown in culture as described above 
and inoculations were prepared by either trypsinising or using Cellstripper for the CT44 
line to remove cells off the culture flasks. Three washes were performed in 1x PBS to 
remove all traces of growth media. At each wash step, cells were spun down at 348 g for 3 
minutes and supernatant removed and resuspended in 20 mL of 1x PBS. Once the wash 
steps were completed, an aliquot of cell suspension was removed and diluted 1:10. A cell 
count was then done by diluting the cell suspension 1:2 with 0.4% Trypan Blue (Sigma-
Aldrich, Castle Hill, NSW) and counted using the Countess Automated Cell Counter (Life 
Technologies, Mulgrave, VIC) to determine total live cells and percent viability. The cell 
suspension was made up to the appropriate volume to give a final concentration of  
5x106 cells/mL in PBS. To determine final volume the following calculation was used: 
Final volume = (viable cells x current volume)/required concentration.  
Each mouse received 5x105 cells (100 µL) subcutaneously by injection on the shaved right 
hand flank. Surviving mice from AB1-HA tumour experiments were re-challenged on the 
contralateral flank with inoculations of AB1 to determine immunological memory.  
 
2.5 Monitoring of Tumour Growth 
Once inoculated with either cell line, mice were monitored 3x weekly with daily 
measurements commencing once tumours reached a size of 70 mm2. Tumour size was 
determined by measuring the length and width of the tumour mass and multiplying 
together to give tumour area. Once tumour sizes had exceeded 100 mm2 while still being 





2.6 Diphtheria Toxin Preparation & Administration 
Diphtheria toxin (DTx) (Sigma-Aldrich, Castle Hill, NSW) was prepared by dissolving the 
lyophilised powder into ddH20 at a concentration of 1 mg/mL and subsequently diluted to 
a working concentration of 100 ng/µL and stored at -80oC. For injection, 1 vial was thawed 
at room temperature and made to a concentration of 1 ng/µL by diluting 1:100 with  
1x PBS. This DTx solution was then injected intraperitoneally (i.p.) by inverting mice so 
as to ensure solution enters the peritoneal cavity. 
 
2.7 Debulking Surgery 
2.7.1 Surgical Procedure 
The debulking of a solid tumour mass is always done in an axenic environment with the 
mice being placed under general anaesthesia. Mice were placed in a sealed jar for 1-2 
minutes to induce anaesthesia through inhaled methoxyflurane (MDI, Springvale, VIC) at 
a concentration of 1 mL per 20-25 g mouse. Maintenance of anaesthesia was provided by 
5% isoflurane (Abbot, Botany, NSW) in oxygen. Surgery was then performed by making 
elliptical incisions around the tumour and the skin flaps elevated (Broomfield et al., 2005). 
The desired amount of tumor is resected, being either a 50% or 75% debulk or a sham 
were the wound is simply closed by suturing through the tumour without any resection. 
Partial debulking is performed by removing half the tumour mass which is representative 
of a 50% debulk and then a further 50% is removed which represents a 75% debulk. 
 
2.7.2 Suturing of Surgical Wound 
For suturing of mice inoculated with AB1-HA or CT44, 3/0 polyglycolic sutures were used 
while for the B16-F10 tumour debulks, 4/0 polypropylene sutures (Surgik, Broken Arrow, 
OK) were used. Suturing of the wound begins at either end of the surgical site. The skin is 
brought together and the needle is threaded through. The initial stitch is secured by tying 3 
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knots, alternating the direction of the knot each time. For Balb/c and 
Balb/c.Foxp3.dtr.Crslc mouse strains a continuous stitch is done, leaving 2-3 mm between 
each one. C57BL/6J mice required interrupted suturing to ensure suture integrity. Once the 




Once surgery has completed, mice are placed in a heat box and are administered  
0.1 mg/kg of the analgesic buprenorphine for pain relief by subcutaneous injection near the 
surgical site. Mice are left to fully wake and once movement has normalised, they are 
transferred back into their original cage. 
 
2.7.4 Post-Surgical Monitoring 
As per the animal ethics permit, all mice that have undergone surgery are monitored 1 hr 
post-surgery, at the end of the day of surgery as well as the following morning. At each 
stage, examination for signs of bleeding or gaps in stitching is undertaken. Required 
resuturing of the surgical site using the protocol described then takes place. Betadine or 
chlorhexadine is placed onto surgical sites that have opened to prevent any infection. If 
mice appear in significant pain the following day, euthanasia as per animal ethics is 
considered. 
 
2.8 Collection and Preparation of Tissues for Flow Cytometry 
To harvest organs, mice are euthanised by cervical dislocation after being anaesthetised in 
methoxyflurane (MDI, Springvale, VIC). They were pinned down and incisions were made 




Target organs (lymph nodes, spleens, tumours) were extracted and placed into 15 mL 
falcon tubes containing 3 – 4 mL of 1x PBS/2% FCS and placed on ice until required. 
Blood was collected into 1.5 mL eppendorf tubes containing 15 µL of 1000 U/mL heparin 
(Pfizer, West Ryde, NSW) to prevent clotting and also placed on ice until required. Once 
prepared, a 100 µL aliquot of each organ sample or a 50 µL blood sample is added to the 
corresponding well on a 96 well U-bottom plate. Each organ or blood sample is collected 
and prepared as follows. 
 
2.8.1 Lymph Nodes 
Unless otherwise stated the axillary and inguinal lymph nodes were taken on the tumour 
bearing side (draining lymph node; dLN) and the non-tumour bearing side (non-draining 
lymph node; ndLN). The axillary node was located in or on top of the armpit and was 
visible once the surrounding connective tissue has been removed. The inguinal node is 
located in the fat pad at the convergence of 3 blood vessels at the left and right flanks. 
Teasing away the fat pad revealed the node that in tumour bearing mice may be enlarged 
or involved with the tumour. Draining and non-draining lymph nodes were disaggregated 
separately using frosted slides into a petri dish and washed with 1x PBS/2% FCS. This was 
then filtered into filter-top tubes and spun down at 348 g for 3 minutes. The supernatant 




The spleens were removed by making an incision in the peritoneum on the right hand side. 
Spleens were disaggregated using frosted slides into a petri dish and collected back into a 
falcon tube to be spun down at 348 g for 3 minutes. The supernatant was removed and red 
blood cells lysed by resuspending the cell pellet in 2 mL of 1x Pharm Lyse™ (BD 
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Bioscience, Lane Cove, NSW) for 3 – 5 minutes. A further 3 mL of 1x PBS/2% FCS is 
added to deactivate and cells are spun down again at 348 g for 3 minutes. Cells were then 
resuspended in 5 mL of 1x PBS/2% FCS and placed on ice until required. 
 
2.8.3 Tumour 
The tumour is located on the right hand flank of the mouse. There is usually a large deposit 
of fat and connective tissue surrounding the tumour that needs to be removed. The tumour 
is then excised from the skin, taking care to remove as much of the skin and hair that is 
attached to it. To get a single cell suspension from solid tumours they are mechanically 
digested using 2 scalpel blades in a petri dish. Once the tumours are at a paste like 
consistency they are collected back into a falcon tube. The 10x Tumour Digest is diluted 
1:10 with R2 media and 2 mL is added to each tumour suspension and they are chemically 
digested for 1 hr on rollers. 
 
After chemical digestion, 50 µL of 0.1 M Ethylenediaminetetraacetic acid (EDTA) is 
added and further incubated for 15 min on rollers. Once incubation is finished, the 
suspension is filtered into a new 50 mL falcon tube using 1x PBS/2% FCS to wash the 
filters allowing for maximum collection of tumour cells. This supernatant is then 
transferred into filter-top tubes and samples are under laid with 1 mL ice-cold EDTA-FCS 
to allow samples to be spun at 527 g for 5 min at 4oC. Once spun, the supernatant is 




Blood was routinely collected via tail vein bleeds from mice placed into a heat box to 
dilate the vein to a point where it can easily be viewed. A small nick is made using a 
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scalpel blade and blood is allowed to drip into the eppendorf tube. No more than 400 µL of 
blood is obtained for analysis. Once blood has been collected, pressure is applied to the 
wound and once bleeding has slowed, ferric chloride is applied to cause coagulation and 
ensures no further bleeding. When necessary blood was obtained via a cardiac puncture. 
This involves inserting a large gauge needle directly into the heart of the mouse that has 
been anaesthetised by methoxyfluorane. The needle has punctured the heart when blood 
enters the syringe without applying any traction. The plunger is slowly pulled back to 
aspirate a blood sample and once enough is collected, the mouse is euthanised.  
 
Blood samples are placed directly onto the 96-well plate with a 50 µL aliquot into each 
well corresponding with each sample. Each sample then receives 150 µL of 1x BD 
FACS™ Lysing Solution (BD Bioscience, Lane Cove, NSW) to lyse the red blood cells 
and incubated at room temperature for 15 min. The plate is spun down at 348 g for 3 
minutes and the supernatant removed. All samples then get resuspended and washed twice 
with 1x PBS/2% FCS to remove the lysing solution. 
 
2.9 Staining for Flow Cytometry 
Samples were prepared as single cell suspensions as per section 2.8 and assessed using 
flow cytometry. For surface staining, all samples were washed twice in 1x PBS/2% FCS 
and then stained (Section 2.9.2). Intracellular staining was performed (Section 2.9.1) to 
detect internal proteins such as FoxP3 and Ki67 when staining for Tregs. 
 
2.9.1 Preparation for Intracellular Staining 
Samples are first spun down at 348 g for 3 minutes and the supernatant is removed. All 
samples are then incubated for 15 minutes with 100 µL of 1x Fix/Perm solution (Jomar 
Bioscience, Stepney, SA) in the dark. The plate is then spun down again as previously and 
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washed twice with 1x Perm Buffer (Jomar Bioscience, Stepney, SA) to remove any 
remaining solution. 
 
2.9.2 Antibody Staining 
The antibody solutions are made up to the required volume using their respective dilutions 
either for the Treg panel or MDSC panel (Appendix Tables 3 and 4 respectively) using 
either 1x PBS/2% FCS for extracellular staining or 1x Perm Buffer for intracellular 
staining. A 20 µL aliquot of either the antibody master mix, single stain controls or 
fluorescence minus one (FMO) controls containing their respective antibodies is placed 
onto each sample well and mixed. For compensation, positive and negative compensation 
beads are used and their corresponding single stains are added. The entire plate is then 
incubated for a minimum of 20 minutes at room temperature in the dark to ensure antibody 
binding. After the incubation, all wells are made up to 200 µL with 1x Perm Buffer and the 
plate spun down. A total of 3 washes is done to ensure all antibodies are removed and all 
samples are resuspended in 200 µL of 1x Stabilising Fixative (BD Bioscience, Lane Cove, 
NSW) and placed into a 4oC fridge until being run on the flow cytometer.  
 
2.10 Flow Cytometry 
All flow cytometry analysis was conducted on a BD FACSCanto II at the Centre for 
Microscopy, Characterisation and Analysis located at the QEII Medical Centre. This 
cytometer had 8 fluorescence parameters and contains a 405 nm, a 488 nm and a 633 nm 
excitation lasers and uses the FACS Diva software package. All samples were prepared on 
a 96-well U-bottom plate as stated and run on the FACSCanto II using the High 
Throughput Sampler (HTS). The stopping gate was set to 50, 000 lymphocytes to ensure 
adequate cell number for analysis. To interpret and analyse the flow cytometry data, 
FlowJo version 8.8.7 (TreeStar Inc, Ashland, OR) was used.  
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2.11 Statistical Analysis 
Each group of mice contained a minimum of 5 animals unless otherwise stated and 
statistical analysis was performed using Prism 6 (GraphPad Software, San Diego, CA). All 
measurements were presented as means ± standard error (SEM). One-way analysis of 
variance with Dunnett’s test was done to compare differences between control and treated 
experimental groups. Cited P values were at the 95% confidence interval, and differences 
were considered statistically significant when P < 0.05. The extent of statistical 
significance is represented by the number of asterisks: * represents P <0.05, ** represents 




















Chapter 3: Kinetics of Tumour Growth & Surgical Debulking 
 
3.1 Kinetics of Tumour Growth 
To test the hypothesis that the removal of suppressive immune cells in combination with 
debulking surgery will improve the anti-tumour immune response we first needed to 
develop testable models of solid malignancies. This involved the investigation of tumour 
growth rates in vivo to determine the best time points for both surgery and administration 
of immunotherapy. To establish these models, BALB/c and C57BL/6J mice were 
inoculated with different tumour cell lines as described in section 2.4 to determine their 
respective growth characteristics 
  
To conduct this experiment, 5x105 cells of the relevant tumour cell line was inoculated s.c 
on the shaved right hand flank of mice. For the AB1-HA and CT44 cell lines, female 
BALB/c mice were used while B16-F10 was inoculated in the same way into female 
C57BL/6J mice. All mice were 6-8 weeks old. Tumours were allowed to grow to a 
maximum of 150 mm2 with length and width measurements taken and multiplied to give 
tumour area. Growth curves for AB1-HA and B16-F10 was obtained experimentally in this 
study while Dr Andrea Khong (UWA Department of Medicine) kindly supplied the growth 









AB1-HA formed solid, spherical tumours that are composed mainly of spindle and 
polygonal cells (Davis, 1992). The growth of AB1-HA was consistent between all 
inoculated mice with palpable tumours at day 3 (Figure 5). Tumours reached the maximum 
allowable size between days 15 and 18. Therefore the day of surgery for the AB1-HA 
model was set to day 13 at which tumours were large enough to accurately debulk size 












Figure 5: Kinetics of AB1-HA Tumour Growth in BALB/c Mice 
A total of 10 BALB/c mice were inoculated with 5x105 cells and growth was measured 
until tumours reached a size >100 mm2 in which case they were euthanised. Each line 




























In contrast, B16-F10 solid tumours were softer and more lobular (Radzi et al., 2012) than 
AB1-HA and had a much darker colour due to the high concentration of melanin 
producing melanocytes. The growth of B16-F10 was also consistent between mice but the 
onset of growth was delayed more than expected and palpable tumours only arose on day 
10 and grew for a maximum of 7 days before reaching size, much faster than AB1-HA. In 
addition to the fast growth rate, once tumours arose we observed increased tumour 
ulceration in B16-F10 that resulted in these mice being euthanised before reaching 












Figure 6: Kinetics of B16-F10 Tumour Growth in C57BL/6J Mice 
A total of 10 C57BL/6J mice were inoculated with 5x105 cells and growth was measured. 
Mice were euthanised when tumours reached a size >100 mm2 or when they began to 



























The growth of the colorectal cancer line CT44 was similar to that of AB1-HA with 
palpable tumours at day 3, however, tumours grew more slowly and reached maximum 
size between days 15 and 20. The shape of the tumour formed was slightly elongated when 











Figure 7: Kinetics of CT44 Tumour Growth in BALB/c Mice. 
A total of 5 BALB/c mice were inoculated with 5x105 CT44 tumour cells and growth 
measured until tumours neared 150 mm2. Kindly supplied by Dr Andrea Khong (UWA 













































Figure 8: Survival of AB1-HA, B16-F10 and CT44 Inoculated Mice. 
Comparison of survival data for AB1-HA, B16-F10 and CT44 tumour bearing mice 
inoculated with 5x105 respective cells s.c for each cell line.  
 
Due to a high rate of tumour ulceration, the growth rate of B16-F10 was repeated using the 
tumour line from 3 different sources in this lab to determine if there were any significant 
differences between them and which would be most suited for future experiments. The 
three stocks used were my original stock at passage 29 and two others at passage 24 and 
passage 16. Again, there were high rates of ulceration in all cell lines despite the viability 
being >90% at inoculation. Results showed consistent growth rates for mice inoculated 
with either passage 29 or 24 B16-F10 cells relative to passage 16 cells (Figure 9 A, B and 
C respectively). However, both passage 29 and 24 cells had an increased incidence of 
ulceration leading to premature euthanasia of the mice. As mice inoculated with the lower 
passage cells demonstrated less ulceration, those were chosen as the primary stock for the 
remaining experiments.  
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Figure 9: Growth of B16-F10 From 3 Different Sources 
B16-F10 was obtained from 3 different research personnel with each having a different 
passage number. C57BL/6J mice were inoculated s.c. with 5x105 B16-F10 tumour cells. 
Each line represents an individual mouse.  











































































Figure 10: Survival of B16-F10 Comparison 
Graph shows the survival of the 3 different groups each inoculated with B16-F10 from a 
different source at 5x105 cells s.c. per line. The lowest rate of ulceration was observed in 
the passage 16 cell line. 
 
Summary 
The primary aim of this chapter was to establish a number of different mouse models that 
could be used to assess whether Treg depletion influences the outcome of partial tumour 
debulking surgery. To achieve this, two different strains of mice were inoculated with three 
different tumour cell lines to assess growth characteristics. 
 
The growth kinetics of AB1-HA and CT44 were similar however CT44 had a slower rate 
of growth that extended survival slightly. The B16-F10 melanoma cell line grew very 
quickly once palpable tumours were evident, however, this was associated with a high rate 






















of ulceration and tumours rarely reached the maximum allowable size as a result. After 
repeating the growth of B16-F10 by using cells grown by 3 different personnel, the stock 
at passage 16 was chosen for use in a pilot debulking experiment to try remove the 
problem of ulceration by surgically removing tumour mass. A pilot debulking surgery was 
























3.2 Surgical Debulking of Solid Tumours 
With the growth kinetics of the proposed tumour models for this project characterised, a 
protocol for performing debulking surgery on these needed to be developed. As surgery for 
solid tumours is often not curative due to outgrowth of residual tumour cells, we aimed to 
mimic this scenario by using a partial debulking tumour model in which a predetermined 
proportion of the tumour is left behind following surgical resection. As this debulking 
surgery protocol had been previously described in the AB1-HA tumour model (Broomfield 
et al., 2005) we therefore sought to apply this technique to both the B16-F10 and CT44 
models. 
 
Surgical debulking of the solid tumours was performed as described in section 2.7 with 
either a sham, 50% or 75% debulk done to determine what effect each has on tumour 
growth and survival. C57BL/6J mice inoculated with B16-F10 and BALB/c mice 
inoculated with CT44 were used as described previously. There were 3 groups per 
experiment corresponding with the extent of debulking to be done with 5 mice per group. 
Where tumours had not grown sufficiently for surgery or an unexpected death resulted 
from surgery, those mice were excluded from analysis. For the B16-F10 model, mice were 
inoculated on day 0 and surgery performed on day 13 due to the onset of tumour ulceration 
in some mice with tumours approximately 40 mm2 in size. For the CT44 model, mice were 
inoculated on day 0 and surgery performed on day 15 when tumours were approximately 
80 mm2. All mice were then monitored until tumours grew to sizes >100 mm2 or the health 
of mice deteriorated as a result of other complications. In the case of CT44, 2 mice had 
tumours that regressed after surgery and so were monitored for 4 weeks after tumour 





3.2.1 Surgical Debulking of B16-F10 Solid Tumours 
The surgical debulking of B16-F10 (Figure 11) was brought forward as a result of 
ulceration beginning in some mice. Tumours growth was delayed due to surgery as 
expected but the post-surgery growth rate remained the same with most mice having to be 
euthanised by day 20 due to ulceration and not that tumours reached maximum size. 
Growth rates appeared to remain constant pre and post-surgery for all groups. There were 
no survivors in any of the groups and one mouse that received a 75% debulk did not 
recover after having to be re-stitched post-op. The outcomes for the B16-F10 debulking 
model were further complicated by additional issues such as mice chewing sutures and 
high rates of ulceration and therefore the decision was made to apply the debulking 








































Figure 11: Debulking Surgery of B16-F10 Solid Tumours 
Either a sham (A), 50% (B) or 75% (C) debulking surgery was performed on C57BL/6J 
female mice aged 6-8 weeks that had been inoculated s.c. with 5x105 B16-F10 tumour 
cells. Each line represents an individual mouse. 























































































Figure 12: B16-F10 Debulk Survival  
Survival plot depicting the influence of partial debulking surgery on B16-F10 bearing 



































3.2.2 Debulking of CT44 Solid Tumours 
The surgical debulking of CT44 tumours was done in the same way as for AB1-HA 
(section 2.6.1 & 2.6.2). It was expected that these tumours would be similar in structure as 
AB1-HA in vivo, based on gross observation, however these tumours were slightly more 
gelatinous although not to the extent of B16-F10. There was also more bleeding from the 
surgical site both during surgery as well as post-op in a small number of mice. This did not 
result in any unplanned euthanasia as was managed by irrigation of the wounds before 
suturing as well as re-suturing of any open areas during post-op monitoring.  
 
Tumour size at the time of surgery (Figure 13 A, B, C) was roughly between 60 and 80 
mm2 with a couple showing very early signs of ulceration. The rate of tumour growth after 
surgery on CT44 was slowed in 46% (7/15) of mice with complete regression observed in 
2 of these. These mice either received a sham or a 50% debulk respectively. Survival was 
also longer than for the B16-F10 tumour model with all but 3 still alive past day 20. Based 
on these results a 75% debulking model was chosen to represent an unresectable tumour 
mass to be used in combination with Treg depletion to determine what effect surgery is 


































Figure 13: Debulking Surgery of CT44 Solid Tumours 
A sham (A), 50% (B) or 75% (C) debulking surgery was performed on BALB/c female 
mice aged 6-8 weeks that had been inoculated s.c. with 5x105 CT44 tumour cells. Each 
line represents an individual mouse. 


























































































Figure 14: CT44 Debulk Survival  
Graph represents the percentage of mice remaining per group and on what day’s mice in 
each of those perspective groups was euthanised due to either tumours reaching maximum 
size or other negative outcomes such as unexpected death after surgery. 
 
Summary 
This chapter aimed to investigate the effect of surgical debulking of solid tumours in both 
the B16-F10 and CT44 tumour models. The many complications, particularly early onset 
of ulceration indicated that the B16-F10 model was not conducive to our debulking surgery 
protocol and therefore we did not pursue this any further. Instead the CT44 tumour model 
previously established was proposed for surgical debulking. 
 
The CT44 model responded well to surgery with tumours debulked using a similar 
protocol as for the AB1-HA model. Tumour growth rate was slowed after surgery in some 
mice with 1 mouse from both the sham and 50% debulk groups having tumours that 






















completely regressed with no re-growth at a later time point. The excess bleeding from 
these tumours during surgery did not prove problematic with irrigation added in for later 
experiments. There was some re-stitching of surgical sites post-op where bleeding had not 
ceased but again was not problematic. This resulted in the CT44 tumour model being a 
prime candidate from future experiments looking at the combination of surgery with 
























Chapter 4: Targeted Removal of Immune Suppression In 
Combination With Surgery 
 
With the tumour and debulking models now established, the effect of suppressive cell 
removal needed to be investigated. This includes both MDSCs and Tregs, both of which 
have suppressive capabilities associated with solid malignancies. 
 
4.1 Myeloid Derived Suppressor Cells 
MDSCs are a heterogeneous population of immature myeloid cells that are the progenitors 
of macrophages, granulocytes and dendritic cells (Gabrilovich et al., 2009). While the 
majority of MDSC’s are located in the bone marrow, small populations, roughly 2-4%, 
exist in both the spleen and blood (Kong et al., 2013) hence these were used to characterise 
these cells in both naïve and tumour bearing mice. This cell population is defined as 
CD11b+ Gr-1+ in mice although this cell population is both difficult to characterise and 
target due to their heterogeneity (Kong et al., 2013).  
 
The gating strategy used for flow cytometry analysis is shown in Figure 1. For this study, 
MDSCs were defined by gating on the negative populations of CD3, CD19 and CD11c 
cells and then comparing Gr-1 and CD11b to further differentiate this population into Gr-1 
low, intermediate and high. The degree of immune suppression capability can be related to 
the expression of Gr-1 with the most potent being the Gr-1 intermediate population. Gr-1 
high MDSCs exert mild suppression against CD8+ T cells but not to the extent of the 




















Figure 15: MDSC Gating Strategy 
MDSCs were identified in spleens by selecting all cells and then gating on the CD3, CD19 
and CD11c negative populations. MDSCs are then separated into the low, intermediate and 
high populations based on expression of Gr-1.  
 
Firstly, MDSC populations in the spleen and blood needed to be characterised. This 
experiment was conducted in parallel to a Treg depletion experiment using Foxp3.dtr mice 
inoculated with 5x105 AB1-HA cells s.c on the shaved right hand flank. Mice were 
harvested as described (Section 2.8) before tumour inoculation and 16 days 
post-inoculation. To determine the proportions of MDSCs, the staining panel outlined in 
table 4 (Chapter 8) was used on blood and spleen samples obtained from naïve and tumour 
























Results show that in the blood there were a higher proportion of Gr-1 high MDSCs relative 
to the low and intermediate populations (Figure 16 A). When comparing naïve to tumour 
bearing mice, there is a significant increase in the Gr-1 low and Gr-1 high MDSC 
proportions in the mice that had established tumours but no increase in the Gr-1 
intermediate population.  
 
The spleen showed a higher proportion of Gr-1 low MDSCs both in naïve and tumour 
bearing mice relative to the Gr-1 intermediate and Gr-1 high populations (Figure 16 B). 
There was no significant increase in proportions for any of the MDSCs proportions when 






































Figure 16: MDSC Characterisation in Blood and Spleen Samples 
MDSCs were characterised in the blood (A) and the spleen (B) of naïve and tumour 












































































To determine what effect the removal of MDSCs have on the survival of mice inoculated 
with the AB1-HA tumour cell line, a preliminary experiment was carried out by Dr Andrea 
Khong testing the effect of all-trans retinoic acid (ATRA) and anti-Gr-1 antibody on 
tumour growth. Described previously in a lung cancer model, the anti-Gr-1 antibody was 
capable of depleting Gr-1 expressing MDSCs and resulted in 50% (4/8) of the established 
Lewis Lung (LL) tumours regressing and development of immunological memory against 
tumour rechallenge as a result of the increased APC, NK and T cell activity (Srivastava et 
al., 2012). The second compound ATRA has been shown to force MDSCs to differentiate 
into their respective non-suppressive cell types with studies conducted in both lung cancer 
(Lee et al., 2012) and in colorectal carcinoma (Nefedova et al., 2007). 
 
ATRA was given at a dose of 10 µg/g per mouse dissolved in dimethyl sulfoxide (DMSO) 
every day for 10 days and anti-Gr-1 antibody at a dose of 200 µg per mouse every 2nd day 
for 3 days. The control groups were treated with either DMSO only or PBS only. 
 
The results show that the anti-Gr-1 antibody sufficiently depleted the Gr-1 high population 
of MDSCs (Figure 17 B) when compared to the DMSO controls (Figure 17 A). ATRA 
resulted in a higher proportion of the Gr-1 high MDSCs when compared to the control 
groups (Figure 17 C). The survival of the treated groups was not increased with the use of 






























Figure 17: MDSC Depletion With Anti-Gr-1 or ATRA 
MDSC depletion was tested by comparing a DMSO control (A) to the anti-Gr-1 treated (B) 
and ATRA treated (C) mice. MDSC’s were analysed from the spleens of AB1-HA tumour 






















Figure 18: Tumour Growth for MDSC Targeted Mice 
Figure shows AB1-HA tumour growth for the DMSO and PBS controls and the 
anti-Gr-1/ATRA treated mice. Each line represents a group of 3 mice for the controls and 5 
mice for the treated groups. 
 
Summary 
Flow cytometry analysis of MDSCs in the blood and spleen of naïve and tumour bearing 
mice showed that there were a higher proportion of Gr-1 high MDSCs in the blood while 
the spleen had a significantly higher proportion of the Gr-1 low MDSCs in both naïve and 
tumour bearing mice. The proportion of Gr-1 low and high MDSCs in the blood did 
significantly increase when comparing naïve mice to tumour bearing mice but this was not 
mirrored in the spleen samples. 
 
The preliminary experiment by Dr Andrea Khong showed that the use of anti-Gr-1 
antibody results in a depletion of only the Gr-1 high MDSC population while those treated 
with ATRA had an increase in proportion of this same population. Neither treatment 


























conveyed a survival benefit to mice inoculated with the AB1-HA tumour cell line. Due to 
the difficulties in obtaining a method which resulted in the clear depletion of MDSCs, it 
was decided that any future experiments involving MDSC depletion would be ceased and 
the primary focus would remain with Tregs as a mouse model allowing for their targeted 
depletion has been established.  
 
4.2 Timing of Treg Depletion In Combination With Surgery 
With the debulking models established for both AB1-HA and CT44, the effect of surgery 
in combination with removing tumour-associated immune suppression needed to be 
determined. One of these methods is the transient depletion of Tregs to remove one of the 
‘brakes’ placed on the immune system by the presence of solid tumours. Another aim was 
to determine at what time this Treg depletion should occur when combined with surgery so 
as to provide the optimal conditions in which an immune response can adequately attack 
and eradicate established solid tumours. To accomplish this, the FoxP3.dtr mouse model 
was used. FoxP3 is a transcription factor involved in the development and function of 
Tregs and was also used as a marker for this cell population. This model allows for a 
specific depletion of FoxP3+ Tregs by administering DTx. 
 
4.2.1 BALB/c.FoxP3.dtr.Crslc Mouse Model 
The FoxP3.dtr mouse model was developed by inserting cDNA encoding the human 
diphtheria toxin receptor (DTR) that had been fused with sequences coding for the green 
fluorescent protein (GFP) at the 3’ untranslated region of FoxP3 (Kim et al., 2007). This 
results in the expression of both proteins on all FoxP3+ cells allowing them to be depleted 
when a dose of DTx is given as well as detect these Tregs by screening for the presence of 
GFP. This method allows for precise depletion of only these cells in contrast to other 
immunotherapies such as low dose cyclophosphamide or anti-CD25 that may affect other 
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immune cell populations including activated T lymphocytes (Needham et al., 2006). 
Depletion occurs in a dose dependent manner with higher doses depleting Treg proportions 














Figure 19: Mode of Action of the FoxP3.dtr Transgenic Mouse Model. 
The FoxP3.dtr transgenic mouse (A) has the DTR gene inserted under the control of the 
FoxP3 promoter. All Treg cells now express the cognate receptor for DTx (B). When a 













As observed in Figure 20, DTx was able to deplete Treg proportions in a dose dependent 
manner in the FoxP3.dtr model. Untreated mice have between 8-12% of their CD4+ T cells 
as FoxP3+ Tregs and the administration of DTx does not affect the proportions of CD8+ T 
cells or non-FoxP3+ CD4+ T cells. Based on these results a dose of 5 ng/g/mouse was 












Figure 20: Dose Dependent Treg Depletion in FoxP3.dtr Transgenic Mouse Model. 
The dose dependent nature of DTx is show in (E) as was provided by Dr Scott Fisher 
(UWA Department of Medicine and Pharmacology). Data represented on a log2 scale to 
































Figure 21: Gating Strategy for FoxP3+ Tregs 
Figure shows the gating strategy for analysis of CD4+, CD8+ and FoxP3+ proportions and 
their respective activation/proliferation status in blood. This same strategy was used for 
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To analyse the proportions of CD4+, CD8+ and FoxP3+ T cells and what percentage of each 
are activated/proliferating, the flow cytometry panel described in table 3 (Chapter 8) was 
established. To isolate these respective cellular proportions and what percentage of each is 
activated/proliferating, the gating strategy in Figure 21 was used. Firstly lymphocytes were 
gated by FSC/SSC and single cells selected. Gating on the CD3+ population allows the 
analysis of CD4+ and CD8+ T cell proportions. These can then be further analysed to 
determine the ICOS and Ki67 proportions of both CD4+ and CD8+ T cells that represents 
activation and proliferating respectively. Finally, FoxP3+ Tregs are analysed by gating on 
CD4+ T cells and further gating on FoxP3+ cells. Again both ICOS and Ki67 expression 
can be quantified in this population. 
 
4.2.3 Surgery and Treg Depletion in the AB1-HA Model 
This experiment aimed to firstly determine if surgery offers a benefit to the eradication of 
AB1-HA solid tumours in combination with depletion of Tregs and secondly what the best 
time to do this was based on tumour size and day of surgery. To conduct this experiment, 6 
groups of 5 Foxp3.dtr mice were inoculated with 5x105 AB1-HA cells s.c on the shaved 
right hand flank. Mice were both male and female between 6-14 weeks of age. 
 
4.2.3.1 Timelines and Growth Kinetics 
The 6 groups were separated into 3 different timelines in which DTx was given when 
tumours were at different sizes either before or after surgery. Surgery was conducted on 
day 16 for the respective groups. Bloods were taken and stained using the Treg panel at the 
time points of 1, 4, 7 and 14 days (DTx+1, DTx+4, DTx+7 and DTx+14 respectively) after 
administration of DTx to measure the proportions of the cell types described as well as 
their activation and proliferation status. Timelines and growth curves for those groups are 
show in figures 11, 12 and 13 respectively. 
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4.2.3.1.1 Neo-adjuvant Small Tumours 
The focus of the first timeline was to investigate the effect of giving a dose of DTx when 
small tumours had grow and compare that to the group who received both the DTx and a 
75% debulking surgery. The timeline (Figure 22) shows that tumours were inoculated on 
day 0 and that a dose of DTx was given on days 9 and 10 with surgery performed on day 
16. The surgery only control group was included in this timeline simply for blood sample 






Figure 22: Timeline for Neo-adjuvant DTx Dosing of a AB1-HA Small Tumour 



































Results for this group showed that all of the mice that received surgery only (Figure 23 A) 
eventually developed tumours that reached maximum size and were euthanised by day 35. 
One mouse was unable to undergo surgery due to spontaneous tumour regression. Survival 
for the other small sized tumour groups (Figure 24) showed the DTx only group had a 
slight halt in tumour growth before 80% (4/5) mice had to be euthanised because tumours 
reached maximum size. This group had a survival of 20% (1/5) in which one mouse had a 
tumour that began regressing shortly after the DTx dose and did not regrow. The group 
receiving surgery and DTx had no survivors but had one mouse survive until day 51 post 
inoculation with a significantly slower tumour growth rate. Another mouse (M4) was 








































Figure 23: Neo-adjuvant DTx Dosing of a AB1-HA Small Tumour 
Figure shows the surgery only control (A), the DTx treated at days 9/10 only (B) and the 
surgery and DTx treated at days 9/10 (C) groups. Each line represents an individual mouse. 
The vertical dotted line represents day of surgery and the arrows represent DTx dosing. 
 






















































































Figure 24: Survival of Small Sized AB1-HA Tumours. 
Comparison of survival data for the surgery only group and groups treated with DTx at a 
small sized tumour.  
 
4.2.3.1.2 Neo-adjuvant Medium Tumours 
The second timeline (Figure 25) investigated the effect of giving a dose of DTx when 
tumours were of a medium size and then comparing the DTx only group with the one that 
received the combination with surgery. Tumours were again inoculated on day 0 and the 






Figure 25: Timeline for Neo-adjuvant DTx Dosing of a AB1-HA Medium Tumour 
Figure shows the timeline for this group with the respective dosing, surgery and blood 
collection days. 


















Surgery + Neo DTx (0/5)
Neo DTx Only (1/5) 





















The results showed a difference in survival between the two groups (Figure 27) although 
not significant. The DTx only group had a survival of 25% (1/4) excluding the mouse that 
did not have a solid tumour while the surgery and DTx group had a survival of 60% (3/5). 
The two non-survivors in this group did have a slower growth rate after DTx and surgery 
and their survival was extended by six and eight days respectively when compared to the 
surgery only group (Figure 23 A). The decline in growth rate was observed with two mice 







































Figure 26: Neo-adjuvant DTx Dosing of a AB1-HA Medium Tumour 
Figure shows the DTx treated at days 14/15 only (A) and the surgery and DTx treated at 
days 14/15 (B) groups. Each line represents an individual mouse. The vertical dotted line 

































































Figure 27: Survival of Medium Sized AB1-HA Tumours 
Comparison of survival data for the surgery only group and groups treated with DTx at a 
medium sized tumour.  
 
4.2.3.1.3 Adjuvant Small Tumours 
The final timeline (Figure 28) contained one group investigating the effect of giving the 
DTx as an adjuvant after surgery when tumours were at a small size. The tumours were 





Figure 28: Timeline for Adjuvant DTx Dosing of a AB1-HA Small Tumour 
Figure shows the timeline for this group with the respective dosing, surgery and blood 
collection days. 
 


















Surgery + Neo DTx (3/5)

























Tumour growth for this group (Figure 29) showed one mouse that did not have a growing 
tumour at any stage and one that had a tumour regress before surgery could be done and 
therefore neither of these received any treatment. Of the three that did, survival was 33% 
(1/3) while the other 66% (2/3) were euthanised when tumours reached maximum size 
(Figure 24). Tumour growth was slowed in only one of the mice that had a tumour reach 

































Figure 29: Adjuvant DTx Dosing of a AB1-HA Small Tumour 
Figure shows the surgery and DTx treated at days 18/19 group. Each line represents an 
individual mouse. The vertical dotted line represents day of surgery and the arrows 
represent DTx dosing. 
 
4.2.3.2 Flow Cytometry Analysis 
As mentioned, bloods were taken from mice at the time points specified on each timeline. 
The purpose of these bloods was to observe the depletion of Treg proportions after DTx 
had been given and how soon they repopulate. The activation and proliferation status of 
CD4+, CD8+ and FoxP3+ cells was also investigated to determine what immune response 
initiates and for how long it remains elevated following Treg depletion. 
 
Firstly, analysis of CD4+, CD8+ and FoxP3+ Treg proportions (Figure 30) showed that at 
baseline (A), the proportion of CD4+ cells were between 70-80% of total CD3+ cells. The 
proportion of CD8+ cells was between 20-30% of total CD3+ cells. The Treg proportions 
sat between 8-12% of total CD4+ cells at baseline which is normal levels in mice.  





























Once mice had been treated with DTx, proportions were again measured at the DTx+1 
time point (B) for each group and showed that the proportion of Tregs of CD4+ cells had 
dropped down to between 2-3%. The proportions of both CD4+ and CD8+ cells did not 
change and remained at the same levels as their baseline readings. The surgery only group 
showed no change in any proportions as it was not treated with DTx. A comparison of the 
level of Treg depletion compared to the control levels of the surgery group is also shown 











































Figure 30: Baseline Proportions and Treg Depletion 
Graphs showing baseline proportions for CD4+, CD8+ and FoxP3+ cells (A) and their 
proportions after dosing with 5 ng/g/mouse DTx (B). Each point represents a mean of all 

























































































































































































The drop in Treg proportions lead to an increase in both the proliferation and activation of 
CD8+ cells. Activation of CD8+ cells was obtained by measuring ICOS expression via flow 
cytometry while proliferation was measured via Ki67 expression and these were obtained 
at the DTx+4 time point. The baseline activation levels for CD8+ cells were between 1-2% 
and increased up to between 8-15%. Proliferation baseline levels were between 5-14% and 
increased to anywhere between 13-30%. The graphs in Figure 31 don’t contain data for 
this time point from the neo-adjuvant DTx dosing at a small tumour due to an unforeseen 
complication. Figure 31 (A) is on a log2 axis to better visualise the data while proliferation 
was adequately represented on a linear scale. 
 
This increased level of CD8+ activation remained elevated for two weeks after the DTx 
dose despite Treg proportions having already returned to baseline at DTx+4. A 
representative graph (Figure 31 C) illustrates this and is data obtained for the DTx only 





































Figure 31: Increase in CD8+ Activation and Proliferation in DTx Treated Tumours 
Graphs shows percentage of activated (A) and proliferating (B) CD8+ T cells as well as the 
increased level of activation of CD8+ T cells over time (C). All DTx+4/DTx+7 levels were 














































































































These experiments aimed to show a difference between receiving DTx only as a treatment 
and the combination of DTx and surgery. The surgery only control group had no survivors 
for those mice that developed tumours where as all other groups did have varying survival 
rates. When DTx was administered at a small tumour it appeared that DTx alone and DTx 
in combination with surgery was not effective enough to result in a high survival rate. 
When DTx is administered to mice with medium tumours that then undergo surgical 
debulking the following day, the rate of survival increases and is significantly better than 
the previous two groups. When compared to each other, the group that received surgery 
had a much better survival rate than the group that didn’t. This correlates with the flow 
cytometry results that show a peak in CD8+ activation would have occurred three days 
after those mice had received surgery where the group that had DTx earlier would already 
have activation coming down, being at DTx+2 on the day of surgery. The final group that 
received DTx post-surgery was slightly inconsistent as only 3/5 mice were able to undergo 
surgery and subsequently only had one of those survive. Their peak CD8+ activation 
occurred eight days after surgery in those mice that were treated. 
 
4.2.4 Surgery and Treg Depletion in the CT44 Model 
This experiment had the same aims as for the AB1-HA model to firstly determine if 
surgery offers a benefit to the eradication of CT44 solid tumours in combination with 
depletion of Tregs and secondly what the best time to do this was based on tumour size and 
day of surgery. It also allowed for the comparison of the response of the two different 




To conduct this experiment, 6 groups of Foxp3.dtr mice were set up all with 5 mice except 
the surgery only group that had 3 due to the low number of mice available. All were 
inoculated with 5x105 CT44 cells s.c on the shaved right hand flank.  
 
4.2.4.1 Timelines and Growth Kinetics 
The experimental setup for Treg depletion in the CT44 model was identical to the work 
done in the AB1-HA model (Section 4.2.1) 
 
4.2.4.1.1 Neo-adjuvant Small Tumours 
The first timeline looked to investigate the effect of giving a dose of DTx when small 
tumours had grow and compare that to the group who received both the DTx and a 75% 
debulking surgery. The timeline (Figure 32) shows that tumours were inoculated on day 0 
and that a dose of DTx was given on days 6 and 7 with surgery performed on day 13. The 
surgery only control group was included in this timeline simply for blood sample 






Figure 32: Timeline for Neo-adjuvant DTx Dosing of a Small CT44 Tumour 




























Results show that all mice in the surgery only group (Figure 33 A) had tumours that grew 
to maximum size with one mouse having a tumour that regressed and subsequently regrew, 
increasing its survival time significantly compared to the other two. The DTx only group 
(Figure 34) had a high survival rate of 80% (4/5) with only one mouse having to be 
euthanised. These survivors remained tumour free once they had completely regressed and 
no regrowth occurred. The DTx and surgery group for this timeline had a slightly lower 
survival rate of 60% (3/5) when compared to the DTx treated only. Tumour growth was 
reduced for one mouse with tumour size reduced to 9 mm2 but then started to grow at the 










































Figure 33: Neo-adjuvant DTx Dosing of a CT44 Small Tumour 
Figure shows the surgery only control (A), the DTx treated at days 6/7 only (B) and the 
surgery and DTx treated at days 6/7 (C) groups. Each line represents an individual mouse. 
The vertical dotted line represents day of surgery and the arrows represent DTx dosing. 
























































































Figure 34: Survival of Small Sized CT44 Tumours 
Comparison of survival data for the surgery only group and groups treated with DTx at a 
small sized CT44 tumour.  
 
4.2.4.1.2 Neo-adjuvant Medium Tumours 
The second timeline (Figure 35) where DTx was given when tumours were at a medium 
size showed no difference between the survival of the DTx treated only and the surgery 
plus DTx treated groups (Figure 37). Both had a survival of 40% (2/5) with the surgery 
extending survival time by 10 days for 2/5 of the mice compared to the DTx only group. 
When compared back to the AB1-HA model for this timeline, there was a clear between 
DTx only and the combination of surgery and DTx. One mouse in the DTx only group had 
a tumour approximately 108 mm2 that then responded to the DTx therapy and regressed 























Neo DTx Only (4/5)
Surgery + Neo DTx (3/5)








Figure 35: Timeline for Neo-adjuvant DTx Dosing of a Medium CT44 Tumour 

























































Figure 36: Neo-adjuvant DTx Dosing of a CT44 Small Tumour 
Figure shows the timeline for this group (A), the surgery only (B), the DTx treated at days 
6/7 only (C) and the surgery and DTx treated at days 6/7 (D) groups. Each line represents 
an individual mouse. The vertical dotted line represents day of surgery and the arrows 




































































Figure 37: Survival of Medium Sized CT44 Tumours 
Comparison of survival data for the surgery only group and groups treated with DTx at a 
medium sized CT44 tumour.  
 
4.2.4.1.3 Adjuvant Small Tumours 
The final timeline (Figure 38) observed the effect of DTx given post-surgery on tumour 
growth (Figure 39) and survival (Figure 34). Results showed that this group had a survival 
rate of 40% (2/5), the same as for the timeline 2 groups. The tumour growth rate for M2 
was very high with surgery or DTx having little effect. The two survivors happened to be 

























Neo DTx Only (2/5)







Figure 38: Timeline for Adjuvant DTx Dosing of a Small CT44 Tumour 






















































Figure 39: Adjuvant DTx Dosing of a CT44 Small Tumour 
Figure shows the surgery and DTx treated at days 15/16 group. Each line represents an 
individual mouse. The vertical dotted line represents day of surgery and the arrows 
represent DTx dosing. 
 
4.2.4.2 Flow Cytometry Analysis 
Again, bloods were taken from mice at the time points specified on each timeline. The 
purpose of these bloods was the same as for AB1-HA to observe the depletion of Treg 
proportions after DTx had been given and how soon they repopulate. The increase in CD8+ 
activation following the removal of these suppressive cells was a second objective of this 
analysis as well as how long these cells remained up regulated and if that correlates with a 
higher rate of survival. 
 
Firstly, analysis of CD4+, CD8+ and FoxP3+ Treg proportions (Figure 40) showed that at 
baseline (A), the proportion of CD4+ cells were between 70-80% of total CD3+ cells. The 
proportion of CD8+ cells was between 20-30% of total CD3+ cells. The Treg proportions 































sat between 8-12% of total CD4+ cells at baseline.  Once mice had been treated with DTx, 
proportions were again measured at the DTx+1 time point (B) for each group and showed 
that the proportion of Tregs of CD4+ cells had dropped down to between 1-3% for the DTx 
treated at small tumour groups and between 0.5-1% for the others. The proportions of both 
CD4+ and CD8+ cells did not change and remained at the same levels as their baseline 
readings. The surgery only group showed no change in any proportions as it was not 
treated with DTx. A comparison of the level of Treg depletion compared to the control 
levels of the surgery group are also shown (Figure 40 C) and show a significant difference 







































Figure 40: Baseline Proportions and Treg Depletion in the CT44 Tumour Model 
Graphs showing baseline proportions for CD4+, CD8+ and FoxP3+ cells (A) and their 
proportions after dosing with 5 ng/g/mouse DTx (B). Comparison of treated groups with 
non-DTx treated surgery group also shown (C). Each point represents a mean of all 


























































































































































































The drop in Treg proportions lead to an increase in both the proliferation and activation of 
CD8+ cells. Activation of CD8+ cells was obtained by measuring ICOS expression via flow 
cytometry while proliferation was done by measuring Ki67 expression and these were 
obtained at the DTx+4 time point (Figure 41). The baseline activation levels for CD8+ cells 
were between 1-4% and increased up to between 25-60%. Proliferation baseline levels 
were between 8-12% and increased to anywhere between 30-70%. Figure 41 (A and B) is 
on a log2 axis to better visualise the data while proliferation was adequately represented on 
a linear scale. This increased level of CD8+ activation remained elevated for two weeks 
after the DTx dose despite Treg proportions having already returned to baseline at DTx+4. 
A representative graph (Figure 41 C) illustrates this and is data obtained for the DTx only 








































Figure 41: Increase in CD8+ Activation and Proliferation 
Graphs shows percentage of activated (A) and proliferating (B) CD8+ T cells as well as the 
increased level of activation of CD8+ T cells over time (C). All DTx+4/DTx+7 levels were 
significantly different from baseline for all groups with P-values <0.0001. 



















































































































































This experiment aimed to show a difference between receiving DTx only as a treatment 
and the combination of DTx and surgery. The surgery only control group had no survivors 
in those animals that developed tumours as where all other groups did have varying 
survival rates. When DTx was administered at a small tumour size it appeared that DTx 
alone was sufficient enough to result in a high survival rate with the surgery counterpart 
having a slightly lower survival rate. When DTx is administered to mice with medium 
tumours that then undergo surgical debulking the following day, the rate of survival was 
the same between the DTx only and surgery plus DTx groups with the group that 
underwent surgery receiving no survival benefit over those that didn’t. The final group that 
received DTx post-surgery had a survival rate the same as the DTx treated mice with a 
medium sized tumour. This group however had one mouse that had survival extended 
significantly, much more than any other that had tumours reach maximum size. 
 
The flow cytometry results show that even though a dose of 5 ng/g/mouse was used for 
both AB1-HA and CT44 models, Treg levels were depleted much lower in the CT44 
experiment. This resulted in a much higher CD8+ response with activation and 
proliferation significantly better than in the AB1-HA model. This was unfortunate as the 
aim was to determine a difference between DTx only and surgery plus DTx treatment. As 
the CD8+ response was so great, this was not possible with some groups as survival rates 








Chapter 5: Characterisation of Tregs In Lymphoid Organs 
 
Systemic depletion of Tregs using currently available immunotherapies such as 
anti-CTLA-4 has been shown to increase the T-cell response to solid tumours (Tuve et al., 
2007) and therefore we wanted to determine whether a similar outcome would be achieved 
following Treg depletion in the FoxP3.dtr mouse model.  
 
The aims of this experiment was to determine what the baseline proportions were for 
CD4+ T cells, CD8+ T cells and Tregs and their activation and proliferation status in the 
dLNs, ndLNs, spleen and tumour. This was to determine whether the flow cytometry 
results obtained from blood samples in the previous section correlates with what occurs in 
the lymphoid organs and tumour. 
 
To conduct this experiment, Foxp3.dtr mice were inoculated with 5x105 AB1-HA cells s.c 
on the shaved right hand flank and were split into 8 groups (Table 1). Mice were harvested 
as described (Section 2.8) before treatment and 1, 4 and 7 days post treatment (DTx+1, 
DTx+4, DTx+7 respectively) with 2 groups harvested per time point. One group was the 
untreated size-matched control and the other was the DTx treated. The experimental 
timeline (Figure 42) shows tumours were inoculated at day 0 with the baseline harvest on 
day 10. DTx was administered on days 12 and 13 with the post-treatment harvests on days 
14 (DTx+1), 17 (DTx+4) and 20 (DTx+7). A dose of 25 ng/g/mouse was used to ensure 
adequate depletion of the Tregs that would result in a significant change in CD8+ 
activation. All graphs are represented on a linear scale and all statistical analysis compared 





Groups No. of Mice DTx Time point 
Group 1 2 Naïve Mice 
Group 2 2 Baseline Tumour Bearing 
Group 3 3 Tumour Bearing DTx+1 
Group 4 3 DTx Treated DTx+1 
Group 5 3 Tumour Bearing DTx+4 
Group 6 3 DTx Treated DTx+4 
Group 7 3 Tumour Bearing DTx+7 
Group 8 3 DTx Treated DTx+7 
 
Table 1: Grouping of Mice According to DTx Time Point 
Table shows the grouping of mice according to the 4 harvest time points associated with 
Treg depletion. For each pairing, one group received 25 ng/g/mouse DTx while the other 





Figure 42: Timeline for Tumour and Lymphoid Harvesting 
Experimental timeline for the dosing and harvesting of AB1-HA inoculated mice. DTx was 
administered on days 12 and 13, with tissues harvested on days 14, 17 and 20 (DTx+1, +4 



















5.1 CD4+ T Cells 
The CD4+ proportions for this experiment (Figure 43) showed a change from baseline 
once DTx had been administered. Naïve and baseline CD4+ proportions for all organs 
showed no significant difference while there was a drop at the DTx+1 time point at which 
Tregs were depleted. These proportions returned to baseline levels for blood, spleen and 
tumour samples with a higher proportion of CD4+ cells at DTx+4 for tumours. The lymph 
nodes showed a continuous decline in CD4+ proportions that correlates with the increase 
in CD8+ proportions (Figure 39 C and D). 
 
CD4+ T cell activation (as represented by ICOS expression) continued to increase 
significantly over time with a 3-4 fold increase at DTx+7 when compared to baseline 
proportions (Figure 44). The tumour samples showed a decrease in ICOS+ CD4+ cells at 
DTx+4 that then rebounded back to the baseline proportion of 90%. The baseline 
proportion of ICOS+ CD4+ cells was higher in the tumours and showed the least amount 
of change when DTx was administered and was the only sample that showed a decrease in 
ICOS proportions. 
 
The proliferation proportions of CD4+ cells represented by the marker Ki67 also increased 
from the DTx+4 time point for blood, spleen, dLN and ndLN samples of roughly 5-6 fold 
(Figure 45). Proliferation of CD4+ cells in the tumour experienced a significant decrease at 
DTx+1 but had returned to baseline levels by DTx+7. Again, tumours showed a much 
higher proportion of Ki67+ CD4+ cells at baseline when compared to the other organ 





























Figure 43: CD4+ T Cell Proportions Over Time 
Figure shows the change in CD4+ proportions over time for blood (A), spleen (B), dLN 






















































































































































































































Figure 44: ICOS Expression In CD4+ T Cells Over Time 
Figure shows the change in ICOS expression for CD4+ cells over time for blood (A), 





































































































































































































































Figure 45: Ki67 Expression In CD4+ T Cells Over Time 
Figure shows the change in Ki67 expression for CD4+ cells over time for blood (A), 















































































































































































































5.2 FoxP3+ Tregs 
The Treg proportions showed a significant decrease (p-value < 0.0001) for all tissues at the 
DTx+1 time point, 1 day after treatment with DTx (Figure 46). Proportions were reduced 
to below 1% of total CD4+ cells and started to rebound by DTx+4. By DTx+7, Treg 
proportions had returned to half the baseline proportion for blood, spleen and dLN tissues. 
The ndLN Treg proportions had returned to baseline by DTx+7 with tumour proportions 
remaining between 2-3% of total CD4+ cells, well below the baseline level. 
 
The proportion of ICOS+ FoxP3+ cells did not change between naïve and baseline for 
blood and spleen samples however there was a significant change between the two for both 
lymph nodes, with the increase being 2 fold (Figure 47). Due to the high depletion of Tregs 
at DTx+1, there were not enough cells to obtain a reading for this time point. At DTx+4 
there was an increase in ICOS+ Tregs for blood, spleen and the lymph nodes that increases 
further at DTx+7. The tumour samples did not have a significant increase in ICOS+ Tregs 
with baseline expression already at 90% of total Treg cells. 
 
The proportion of Ki67+ Tregs (Figure 48) mirrored that seen with ICOS expression in the 
blood and spleen had no significant difference between naïve and baseline proportions 
whereas the was a difference observed in the lymph nodes. All tissues excluding tumours 
displayed a significant increase in the proportion of Ki67+ Tregs by DTx+4 and DTx+7. 
Tumours again showed the least amount of change in the Ki67+ proportion of Tregs with a 






























Figure 46: Treg Proportions Over Time 
Figure shows the change in Treg proportions over time for blood (A), spleen (B), dLN (C), 
















































































































































































































































Figure 47: ICOS Expression In FoxP3+ Cells Over Time 
Figure shows the change in ICOS expression in Treg cells over time for blood (A), spleen 










































































































































































































































Figure 48: Ki67 Expression In FoxP3+ Cells Over Time 
Figure shows the change in Ki67 expression in Treg cells over time for blood (A), spleen 

























































































































































































































5.3 CD8+ T Cells 
Finally, the changes in proportion in CD8+ cells as well as their percentage of activation 
and proliferation were analysed (Figure 49). For all tissues except the spleen, there was no 
significant difference between the proportion of CD8+ cells for the naïve, baseline and 
DTx+1 time points. At DTx+4, all tissues had a significantly higher proportion of CD8+ 
cells when compared to baseline proportions with the lymph node having a proportion of 
CD8+ cells that remained elevated through to DTx+7. The tumour displayed the largest 
change in CD4+ vs. CD8+ proportions with an increase up to 40% for CD8+ cells. 
 
The most significant increase in ICOS expression in CD8+ cells was at the DTx+4 time 
point for the blood, spleen and lymph node tissues with an increase between 4-5 fold 
(Figure 50). This increase remained constant for the lymph nodes at DTx+7 but in the 
blood and spleen there was a small significant increase in ICOS+ CD8+ cells. While the 
proportion of ICOS expressing CD8+ cells did slightly decrease and then subsequently 
increase for the tumour samples, these changes were not significant. 
 
The proportion of proliferating CD8+ cells was significantly higher (p-value < 0.001) for 
blood, spleen and lymph node tissues at the DTx+4 and DTx+7 time point (Figure 51). 
There was no significant difference between the proportions of proliferating CD8+ T cells 
at any time point within the tumour but proliferation status at baseline and DTx+1 was 































Figure 49: CD8+ Proportions Over Time 
Figure shows the change in CD8+ proportions over time for blood (A), spleen (B), dLN 































































































































































































Figure 50: ICOS Expression In CD8+ Cells Over Time 
Figure shows the change in ICOS expression in CD8+ cells over time for blood (A), spleen 














































































































































































































Figure 51: Ki67 Expression In CD8+ Cells Over Time 
Figure shows the change in Ki67 expression in CD8+ cells over time for blood (A), spleen 
















































































































































































































5.4 Treg Depletion & CD8+ T Cell Activation 
The key aspects involved in this anti-tumour response is firstly the depletion of FoxP3+ 
Treg cells and the subsequent increase in CD8+ activation represented by a higher 
expression of the activation marker ICOS. 
 
The results show that Treg baseline levels (Figure 52 A) were similar for blood, dLNs and 
ndLNs with proportions lying between 10-15% while proportions in the spleen were 
slightly higher at 18-20%. Tumour samples had the highest proportions of Tregs of total 
CD4+ cells with levels ranging from 25-40%. Once a dose of 25 ng/g/mouse DTx was 
given, Treg proportions were significantly depleted compared to baseline levels. The 
proportion of Tregs of total CD4+ T cells was depleted to below 1% for all organs with 
blood depleting the most and tumours depleting the least. 
 
Figure 52 B shows that CD8+ activation status was significantly increased in all organs 
when compared to the non Treg depleted controls at the DTx+4 time point that 
corresponds to the highest peak in activation. The biggest difference was in the spleen and 
blood with activation levels increasing 4-5 fold of total CD8+ cells. Activation in the dLNs 
and ndLNs increased 4 fold. CD8+ activation status in the tumour had the least amount of 































Figure 52: Treg Depletion in Lymphoid Organs, Tumours and Blood 
Graphs show percentage of depleted Tregs at DTx+1 (A) and activated CD8+ T cells at 
DTx+4 (B). Graph A is on a log2 scale to allow for adequate visualization of the range of 
Treg proportions while Graph B is on a linear scale. All baseline and Treg depleted or 




















































































The results from this experiment have shown that depleting the proportion of FoxP3+ 
Tregs in the FoxP3.dtr model mediated a number of immunological effects. 
Firstly, there was a depletion of CD4+ T cells that resulted in a significant increase in 
activated and proliferating CD4+ cells in all tissues that remained elevated up to DTx+7. 
 
Similarly, as Tregs were the target of this model, their proportions were depleted to below 
1% for all tissues as a result of DTx administration. At DTx+4, the proportion of activated 
and proliferating Tregs had increased significantly to above 80% of total FoxP3+ cells and 
remained at that level for the DTx+7 time point. Proportions of FoxP3+ cells of CD4+ 
cells started to repopulate by DTx+4 and had returned to approximately half their baseline 
levels by DTx+7 for most tissues. 
 
The proportion of CD8+ T cells increased significantly in the lymph nodes from the 
DTx+4 time point as well as in the tumour but no major changes in other tissues. Their 
activation and proliferation proportions increased drastically in all tissues except the 
tumour with changes in the percentage of activated and proliferating CD8+ cells being 
minor in terms of baseline levels. 
 
Finally, of these immunological changes that resulted from DTx administration, the main 
focus was on the depletion of Tregs and the subsequently increase in CD8+ activation. 
This experiment showed that at a dose of 25 ng/g/mouse of DTx into the FoxP3.dtr mouse 
model inoculated with AB1-HA there is a significant depletion of Tregs in the blood, 
spleen, dLN, ndLN and the tumour. Baseline Treg levels for the tumour were significantly 
higher than the other organs while there was no difference between the dLN and ndLN. 
Depleted levels mirrored the baseline levels with blood having the lowest proportion of 
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Tregs at baseline to having the lowest proportion after treatment while in the tumours, 
baseline levels were the highest and remained so after DTx treatment. 
 
CD8+ activation was significantly increased in all organs at the DTx+4 time point with the 
highest levels being in the spleen and the lowest being in the ndLN. The tumour had the 
least amount of change in CD8+ activation, with only an average increase of 9.2% between 
the control and treated groups. While this experiment showed a correlation between the 
systemic depletion of Tregs and the resulting systemic increase in CD8+ cell activation 
status, the intratumoural increase was the lowest of the organs analysed despite this being 
the pathological site and target for treatment. Further experimental research can be done to 
determine if a higher intratumoural dose of DTx leads to a higher increase in CD8+ 
activation without the resultant autoimmunity as was observed with intratumoural 
















Chapter 6: Discussion 
 
6.1 Introduction 
Surgery remains a primary treatment option for many solid malignancies including 
melanoma and colorectal cancer but is not routinely done in others such as malignant 
mesothelioma. The reason being the risks often outweigh the benefits as complete 
resection of this tumour type is very difficult (Robinson et al., 2005). There is often a 
recurrence of disease with surgical resection of solid cancers due to micro-metastases 
that have remained undetected or the inability to safely remove the entire mass (Yano et 
al., 2009). This has resulted in the prescription of adjuvant therapies including 
chemotherapy, radiotherapy and immunotherapy to be used in combination with surgery 
to achieve a curative option in cases where complete resection is not possible (Rudd, 
2010). One type of adjuvant therapy is the use of immunotherapy agents to either 
stimulate a stronger immune response to cancer or to remove the suppression that is 
imposed by these solid cancers. The role of the immune system in the fight against 
cancer was debated intensely but it is now well accepted that an immune response to 
cancer can be an effective and hopefully curative option for those malignancies 
currently without adequate treatments (Whiteside, 2006). 
 
The aim of this study was to investigate the effect of removing tumour-associated 
immune suppression by targeting the immune suppressors Tregs and MDSCs and how 







6.2 Pre-Clinical Models of Solid Malignancies 
The cancers used in this study, mesothelioma, melanoma and colorectal cancer, were 
chosen because of their current treatment status in human patients. Surgery has a role in 
all of these cancers to either resect the entire tumour or perform partial debulking where 
possible and treat with adjuvant therapies. Surgery is often unsuccessful at later stages 
due to the diffuse nature of mesothelioma or the metastatic potential of melanoma or 
colorectal cancer (Cunningham et al., 2010; Hiddinga et al., 2013). At later stages all of 
these cancers are highly resistant to conventional therapies and therefore novel 
approaches need to be developed. 
 
The models used in this study are not true disease state models as all tumours were 
grown subcutaneously with a very small chance of them metastasising to other tissues. 
The location of the tumours allowed for easy access for measuring as well as 
performing the partial debulking surgery without placing mice under excessive stress. 
 
6.3 Kinetics of Tumour Growth 
The first aim of this study was to determine the growth rates of the AB1-HA, B16-F10 
and CT44 tumour cell lines that represent mesothelioma, melanoma and colorectal 
cancer respectively.  
 
AB1-HA is grown in mice on a BALB/c background and forms a solid, spherical 
tumour when inoculated s.c. that allows for precise measurement of area to track 
growth. This cell line has a stable growth rate that was suitable for surgery as it allows 
for flexibility in terms of experimental planning. The variability of growth from one day 




In contrast, the B16-F10 tumour cell line is a mouse melanoma line that is grown in 
vivo on C57BL/6J mice and forms aggressively progressing solid tumours when 
inoculated s.c (Culp et al., 2006). In this study the growth of B16-F10 was delayed for 8 
days post inoculation with established tumours reaching maximum size 10 days later.  
 
There was also a high rate of tumour ulceration associated with the growth of this 
tumour than has been observed previously (Kline et al., 2012; van Elsas et al., 1999). 
The cause of this ulceration was not investigated due to time constraints but a 
correlation between tumour ulceration and the level of serum matrix 
metalloproteinase-8; a protein responsible for degradation of type I collagen has been 
shown to occur specifically in melanoma patients. This may present a possible target to 
reduce this incidence (Vihinen et al., 2008).  
 
The growth of the CT44 solid tumour resulted in tumours at a size of 50 mm2 by day 10 
with maximum allowable sizes reached up to 23 days after inoculation. This growth rate 
was slower than both AB1-HA and B16-F10 with tumours not forming a spherical mass 
but rather an elongated malignancy that was shown in debulking experiments to display 
metastatic potential by growing towards the peritoneal cavity. The slower rate of growth 
of this tumour in vivo may relate to its immunogenic nature. For example, a version of 
the wild type CT26 was engineered to secrete granulocyte and macrophage 
colony-stimulating factor (CSF). That results in the generation of CTLs that mainly 
recognise an antigen present on CT26, gp70 that is also present on CT44 cell lines 




The growth kinetics of these solid tumours were used in the timing of subsequent 
experiments and provided a better idea of when to perform debulking surgery. The aim 
was to have tumours at least 50 mm2 in size to ensure they were established.  
 
6.4 Surgical Debulking of Solid Tumours 
To investigate the hypothesis that debulking surgery is a relevant and successful 
treatment option in combination with an adjuvant immunotherapy, debulking models 
had to be established. A protocol for the partial debulking of AB1-HA solid tumours 
has been established previously (Broomfield et al., 2005) and we sought to apply this 
principle to both the B16-F10 and CT44 tumour models. 
 
The surgical debulking of AB1-HA is simple to perform due to the solid, round 
morphology of the tumour that has minimal bleeding and short recovery times. In 
contrast, debulking surgery performed on B16-F10 tumours proved challenging, as 
tumours were less solid and sizes more variable than AB1-HA or CT44. While difficult, 
surgical debulking of this tumour model was possible however several factors resulted 
in this model being removed from further investigations. Those that received any 
debulking surgery did not survive past day 20 and this was mainly a result of extensive 
tumour ulceration. The healing of surgical wounds was also slowed possibly due to 
constant grooming by the mice that occasionally lead to complete removal of sutures. In 
these instances the mice were no longer included in this study. 
 
The CT44 tumour cell line responded well to debulking surgery and is a suitable model 
to test as patients with late stage colorectal carcinoma often experience recurrence of the 
disease following surgery. One cause being that the disease has either metastasised to 
other regions or that a complete resection was not possible (Cunningham et al., 2010). 
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The immunogenic nature of this tumour is more pronounced with the addition of 
debulking surgery as there was a 13.3% rate of complete tumour regression. One 
immune stimulating characteristic of debulking surgery is the trauma caused at the 
tumour site and the release of tumour antigens into systemic circulation. This release 
allows for higher rates of cross-presentation of tumour antigens to APCs in the lymph 
nodes and a subsequent stronger CTL response to the tumour (Brown et al., 2012; 
Khong et al., 2013; Lake et al., 2005). This correlates with what was mentioned 
previously with variants of CT44 based on a wild type cell line version that was 
specifically engineered to cause the generation of tumour-specific CTLs. The process of 
debulking surgery may enhance this response. There may be TAAs associated with 
CT44 that are better recognised by the immune system than those present on AB1-HA 
or B16-F10 (Khazaie et al., 2006). 
 
Based on the response to debulking surgery, the AB1-HA and CT44 tumour cell lines 
were chosen to proceed with subsequent studies and the partial debulking of these 
cancers was representative of what occurs in human patients particularly at later stages 
of these cancers. 
 
6.5 Debulking Surgery With Transient MDSC and Treg Depletion 
With the debulking models established for two tumours where complete resection of the 
cancer is often difficult, appropriate adjuvant therapies are needed to ensure a curative 
option is available. The immune suppression associated with the presence of a solid 






6.5.1 Characterisation and Depletion of MDSCs  
The heterogeneity of MDSCs proved troublesome to both characterise and target as a 
proposed immunotherapy. MDSCs are commonly described as being CD11b+ Gr-1+ in 
mice and so a method of negative gating in flow cytometry to remove DCs, T and B 
lymphocytes was used to further define this population. While the majority of MDSCs 
are found in the bone marrow, small populations are present in both the blood and 
spleen of mice (Kong et al., 2013). This study showed that MDSC proportions in the 
blood were generally comprised of the Gr-1 high phenotype for both naïve and tumour 
bearing mice with a significant increase in Gr-1 high and Gr-1 low phenotypes when a 
solid tumour was present. The proportions in the spleen were reversed with a high Gr-1 
low phenotype while the other proportions remain low. The spleen did not show a 
significant change in the proportion of any MDSC phenotype when comparing naïve 
and tumour bearing mice.  
 
The primary mechanisms for MDSC immune suppression are cell-to-cell contact with 
the interaction of surface markers and the local secretion of immune mediators such as 
arginase-1 and iNOS with their primary role being within the tumour (Kong et al., 
2013). Due to the available cell number when harvesting tumours for flow cytometry 
analysis, characterising MDSC proportions within sold tumours was not possible as part 
of this project it remains however a potential source of vital information into the role of 
MDSCs within these tumour models. 
 
The depletion of MDSCs was attempted in a preliminary experiment conducted by Dr 
Andrea Khong (UWA School of Medicine and Pharmacology) by trialing the use of two 
compounds, namely anti-Gr-1 antibody and ATRA. The results of that study showed 
that the anti-Gr-1 antibody was successful in depleting MDSCs that had a high 
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expression of the Gr-1 antigen but did not effect the more suppressive population that 
have an intermediate expression of this molecule (Dolcetti et al., 2010). The use of 
ATRA resulted in a greater proportion of Gr-1 high MDSCs with a slight increase in the 
intermediate population. Tumour growth was not delayed or affected by either treatment 
with all tumours progressing at the same rate as the controls. This result could 
potentially be improved by further optimisation of the treatment compounds as well as 
exploration of other routes of administration. An example might be giving these 
intratumourally to focus the effect within the tumour instead of a systemic dose. The 
focus of the remainder of the study was on the role of Tregs in immune suppression as a 
mouse model allowing their targeted depletion has been established previously. 
 
6.5.2 Depletion of Tregs to Enhance the Tumour Immune Response 
The role of Tregs in cancer immunology has been well studied and Treg-mediated 
immune suppression is a crucial evasion strategy employed by solid cancers to limit the 
immune response (Chen et al., 2005). This indicates Tregs as a target for 
immunotherapies to improve the outcomes of cancer currently without a cure. Presently, 
treatments to deplete or alter Treg activation include low dose cyclophosphamide, 
anti-CD25 antibody and the CTLA-4 antibody. The problem with these compounds is 
that as well as targeting Tregs, they also target activated effector T cells in the case of 
anti-CD25. Low dose cyclophosphamide is not as effective in human patients as it was 
in mouse models of cancer (Zou, 2006). 
 
Therefore to analyse the effect of specific Treg depletion in combination with partial 
debulking surgery, the FoxP3.dtr mouse model was utilised. This allows for the 
administration of DTx that results in a transient depletion of only FoxP3+ Tregs and can 
be done in a dose dependent manner (Kim et al., 2007). This combination of Treg 
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depletion and 75% debulking surgery was conducted on both the AB1-HA and CT44 
tumour models. 
 
6.5.2.1 Treg Depletion in the AB1-HA Tumour Model 
The effect of Treg depletion was tested as a single treatment and in combination with 
debulking surgery. A further test was conducted to determine the effect on tumour 
growth when DTx is administered at different time points that correlate with a 
difference in size of the tumour either before or after surgery. The surgery only control 
had 100% of tumours grow to maximum size. Those that underwent the 75% debulking 
surgery indicated that AB1-HA is not extensively immunogenic and a strong immune 
response does not result from debulking surgery alone. When DTx was given once a 
small tumour had established, either with or without debulking surgery, there was one 
survivor that received DTx only while all other mice from this time line had tumours 
progress to maximum size. This difference was not significant and flow cytometry 
analysis of the increase in the proportion of activated CD8+ T cells show that at DTx+4 
activation reaches its peak level and starts decreasing before partial debulking surgery is 
done. 
 
In contrast, a high rate of tumour regression was observed in DTx treated mice bearing 
medium sized tumours and in combination with surgery. The DTx only group had a rate 
of survival of 25% of those that had a palpable tumour while in combination with 
surgery this was extended to 60%. The timing of administration of DTx correlated with 
a peak in CD8+ T cell activation only two days after debulking surgery when tumours 
were smaller in size. The trauma of debulking surgery could have caused the amount of 
TAAs in the system to reach a threshold level that is required for that an anti-tumour 
immune response (Robinson et al., 1999). This availability of TAAs as well as the 
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activation of CTLs to an effective level led to the complete regression of tumours. It 
also resulted in the induction of memory T cells that prevented a rechallenge with AB1 
from establishing a new solid tumour. 
 
The outcome of giving DTx post-surgery on a small tumour was also investigated. This 
resulted in a survival rate of 33.3% of the mice that had palpable tumours for which 
surgery could be performed. As TAAs would be abundant at the time of administration 
of DTx, the reason there was no effective response could be timing. When peak CD8+ 
T cell activation occurred, it had been 8 days post-surgery which would have allowed 
tumours to re-establish and begin exponential growth getting to a size that would have 
resisted an immune response to the tumour. 
 
In the AB1-HA model, once Tregs had been depleted the resultant increase in CTL 
activation remained at a higher than baseline level at least two weeks after DTx had 
been given. This is in spite of Treg activation and proliferation having increased 
dramatically by DTx+4 with the proportion of Tregs of total CD4+ T cells already back 
to the baseline level. This indicates that despite the high rate of both activated and 
proliferating Tregs in the systemic circulation, they are not capable of shutting down a 
CTL response immediately. It is a process that occurs over time, lasting much longer 
than it took to initiate that immune response. 
 
6.5.2.2 Treg Depletion in the CT44 Tumour Model 
With the aim of showing translatability of this approach to other tumour models, the 
work whereby Tregs are depleted either with or without debulking surgery was carried 
out in the CT44 tumour model. Based on the response to debulking surgery in which a 
small number of tumours completely regressed, the hypothesis was that the immune 
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response would be more effective towards this tumour than it was against AB1-HA. The 
same time lines were investigated by administering DTx either at a small, medium or 
small after surgery tumour to determine when the best time point was for Treg 
depletion. Further investigation was done to determine if there is a difference between 
those receiving only DTx and those receiving the combination. 
 
The DTx stock used for CT44 study appeared to be more effective than seen previously 
with AB1-HA, resulting in greater Treg depletion. This correlated with CD8+ T cell 
activation that was much higher and remained elevated for longer (>2 weeks) and was 
thus able to improve the survival rate without the need for surgery.  
 
Near complete regression occurred in one tumour that only received debulking surgery, 
possibly due to a strong CD4+ and CD8+ T cell response that eventually shut down 
(Klein et al., 2003). At the stage of a small tumour, the resultant immune response was 
capable of causing complete regression in 80% of the established tumours with a 60% 
survival rate for the combination with debulking surgery. The higher CTL response due 
to a greater depletion of Treg proportions may have masked the potentially important 
role of debulking surgery at this time. This could be rectified by optimising the new 
DTx stock and using a lower dose to bring Tregs to between 2-3% of total CD4+ cells. 
 
The DTx treated at a medium tumour stage showed that there was a survival rate of 
40% for both the DTx only and the DTx plus surgery groups. Survival was extended for 
those who received the debulking surgery with 40% of the mice having a noticeable 
delay in tumour progression. Despite the availability of tumour antigens post-surgery as 
well as peak CTL activation occurring soon after, the percentage of regressed tumours 
was less than expected as this group performed the best in the AB1-HA tumour model. 
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Tregs depleted post-surgery resulted in a survival rate of 40% with a noticeable delay in 
growth for a further 40% of tumours. The two tumours that regressed correlated with 
smaller tumour sizes at time of surgery. This may indicate the size of established 
tumours is a representation of the suppressive effect they impose on the immune system 
with larger malignancies being more resistant to an effective immune response because 
they have already overcome immunosurveillance (Narendra et al., 2013). 
 
In summary, the result of this work showed that debulking surgery alone offers no 
survival benefit in terms of a complete regression in either the AB1-HA or CT44 
tumour models. Treg depletion using the FoxP3.dtr mouse model increases the 
activation and proliferation status of CD8+ T cells and does improve survival that is 
further increased when done in combination with debulking surgery. The best response 
for the AB1-HA tumour model was the combination of debulking surgery and Treg 
depletion just prior to surgery. Survival rates for CT44 were best when depletion 
occurred at smaller tumour sizes irrespective of debulking surgery. There may be a 
correlation between tumour size when DTx was administered and survival. This can be 
further investigated to determine the threshold size of tumours and whether they will 
regress or not. The correlation between the extent of CD8+ activation and tumour 
regression was unclear as similar activation levels resulted in the regression of some 
tumours but not others. With all analysis of immune responses done from blood 
samples, these processes had to be investigated in both the lymphoid organs and the 
tumour itself to determine if these immune responses occurring are a representation of 






6.6 Characterisation of Tregs in the Tumour and Lymphoid Organs 
We then sought to investigate whether DTx administration depleted Tregs in other 
lymphoid organs in the same manner as we observed for peripheral blood. In terms of 
CD4+ T cell proportions, a possible explanation for the decrease observed was due to a 
depletion of FoxP3+ CD4+ T cells. Those are the only cell type affected in this model 
(Kim et al., 2007). The increase in both activated and proliferating CD4+ included both 
FoxP3+ and FoxP3- populations. It is possible that the removal of Tregs removes 
suppression imposed on CD4+ T cells that allows them to promote activation and 
proliferation of the CTLs both in systemic circulation and intratumourally (Whiteside, 
2006). Comparison of CD4+ T cell proportions showed a significantly lower percentage 
in the tumour with these cells having both high proportions of activated and 
proliferating cells. These CD4+ T cells may have roles in both the expansion and 
cytolytic capabilities of CTLs as well as the overall regulation of the immune response 
(Kennedy et al., 2008). 
 
Treg proportions varied between tissues with proportions in the blood and lymph nodes 
being between 8-12% of total CD4+ T cells at baseline. Treg proportions in the spleen 
were 2-fold higher than in the blood and lymph nodes, whereas the proportion in 
tumours were 4-fold higher. A higher density of Tregs was expected in the tumour and 
is often used as a marker for disease outcome in human cancers with a larger proportion 
of tumour-infiltrating Tregs correlating with a negative prognosis (Savage et al., 2013). 
Following Treg depletion the activation and proliferation of Tregs increased 
significantly in all tissues except the tumour. A possible reason that tumour-infiltrating 
Tregs are already highly activated or proliferating could be due to the ability of solid 
tumours to recruit and maintain active Tregs intratumourally (Evans et al., 2006). 
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Lastly, the activation and proliferation status of CD8+ T cells was characterised to 
determine the systemic CTL response that resulted from Treg depletion. Blood showed 
the lowest proportion of CD8+ T cells with the spleen having the highest at baseline. 
The greatest change occurred in the lymph nodes. While there was a significant increase 
in proportion of CD8+ T cells in both the dLN and ndLN when compared to blood, the 
maximum increase was observed in the dLN. A possible explanation is that APCs are 
tracking from the site of the tumour straight to the dLN due to its proximity to the 
tumour site. The presentation of antigen via cross-presentation to CD8+ T cells results 
in a massive expansion of this population (van der Bruggen et al., 2006). CD8+ T cell 
proportions in the tumour were the lowest of all tissues with a significant increase at the 
DTx+4 time point. This may indicate that removal of suppressive Tregs results in an 
increase in TILs to that area, a phenomenon that has previously been correlated with a 
positive prognosis and increased survival in cancer (Mahmoud et al., 2011). Both 
activation and proliferation increased in all lymphoid tissues and the blood following 
Treg depletion and remained so up to the final time point of DTx+7. The tumour sample 
experienced little change in either activated or proliferating proportions of CD8+ T cells 
possibly due to the fact that these were already highly activated/proliferating. 
 
The overall impression from this work indicated that the proportions of CD4+ T cells, 
CD8+ T cells and Tregs as well as their activation/proliferation status was comparable 
between the blood and lymphoid tissues. Their proportions within blood give a good 
representative picture of what is happening systemically when depletion of Tregs is 
used as a form of immunotherapy. A clearer idea of the immune response within 





Chapter 7: Conclusion 
 
7.1 Conclusion 
Solid cancers such as malignant mesothelioma and colorectal cancer are incredibly 
difficult to treat at later stages of the disease as they often become treatment resistant. By 
introducing partial resection surgery in combination with an adjuvant immunotherapy we 
have the opportunity to induce the immune system to respond to TAAs that remain in order 
to eradicate micro-metastases that may have formed. Two potential immunotherapy targets 
are MDSCs and Tregs, which have both been implicated in the ability of solid tumours to 
evade host immune responses. Both of these populations are involved in suppression of the 
immune system that prevents an appropriate CTL response to tumours that have already 
adapted to evade the immune response. This study showed that removal of Treg 
suppression could allow CTLs to both infiltrate and impact on solid tumours and that 
although Tregs return to baseline soon after transient depletion, the CTL response remains 
active. This potentially provides a window for a second immunotherapy agent. Finally, it 
was shown that transient Treg depletion could successfully be combined with surgical 
debulking to further improve the survival rate and overall outcome of solid malignancies. 
 
7.2 Future Directions of This Study 
There are several areas presented in this study that can be further investigated. The 
systemic depletion of MDSCs resulted in no survival benefit despite the literature 
indicating a major role for this cell type in immune suppression (Gabrilovich et al., 2009; 
Srivastava et al., 2012). The treatments used may be further optimised and the possibility 




Systemic depletion of Tregs proved very effective in controlling tumour growth but the 
potential for autoimmunity remains a barrier that needs to be overcome. Investigation of 
intratumoural Treg depletion in the FoxP3.dtr model may alleviate this if a dose can be 
given to contain the CTL response locally to the tumour without the systemic effects 
observed in this study. Researchers are already investigating this with other Treg depleting 
compounds (Needham et al., 2006). 
 
As surgery is still a primary treatment option for many solid cancers, novel surgical models 
need to be established to test partial resection on a variety of cancers. How this can be 
combined with adjuvant therapies to improve outcomes or reduce the extent to which 
surgery has to be done can be investigated. This may lead to less invasive procedures and a 
shorter recovery time for patients. This was the first study investigating the effect of Treg 
depletion and surgical debulking in colorectal cancer using the FoxP3.dtr mouse model and 
showed translatability between this model and the AB1-HA model. Furthermore, this 
model provided a proof on concept that systemic removal of Tregs is beneficial with new 






















Chapter 8. Appendix 
 
Table 2: Reagents 
 Reagent Working Stock Source Catalog No. 
100 U/mL Benzylpenecillin 
- SCGH Pharmacy 
(Nedlands, WA) 
- 
10x BD FACS ™ Lysing 
Solution Diluted 1:10 with H20 
BD Bioscience 
(Lane Cove, NSW) 
349202 
10x BD Pharm Lyse™ Diluted 1:10 with H20 
BD Bioscience 
(Lane Cove, NSW) 
555899 




1x Phosphate Buffer Saline 
2x PBS tablets dissolved 
in 400 ml ddH20 
Sigma-Aldrich 




(Castle Hill, NSW) 
M7522 
20mM Gibco® Hepes 
- Sigma-Aldrich 
(Castle Hill, NSW) 
H3375-1KG 
3x BD Stabilising 
Fixative™ Diluted 1:3 with H20 
BD Bioscience 
(Lane Cove, NSW) 
338036 
50 mg/mL Geneticin® 
Selective Antibiotic 
- Life Technologies 
(Mulgrave, VIC) 
10131027 
50 ug/mL Gentamicin 




- Corning Cellgro 
(Manassas, VA) 
25-056-CI 
Collagenase Type ll Powder 
Dissolve Collagenase in 
50 ml of R2 media and 
DNase into 10 ml R2 
Media. Add both 
together and make up to 
100 ml with R2 media to 














Toxin powder in ddH20 
at a concentration of 1 
mg/ml and store at -80oC 
Sigma-Aldrich 




Made up to 1x Fix/Perm 
solution by adding 1 part 
Fixation/Permeabilisatio













Foetal Calf Sera 
- Life Technologies 
(Mulgrave, VIC) 
- 
Gibco® DMEM High 
Glucose Cell Culture Media 
w/ L-glutamine 





- Life Technologies 
(Mulgrave, VIC) 
35050-061 
Gibco® RPMI 1640 Cell 
Culture Media w/ L-
glutamine 




Prepared by adding 2% 
v/v of FCS into 1x PBS 
Sigma-Aldrich 
(Castle Hill, NSW) 
- 
1000 U/mL Heparin 










Table 3: Treg Panel 
Antibody 
Marker Fluorophore Isotype Clone Dilution Source 
Catalog 
No. 
CD3 PE-Cy7 Hamster IgG 145-2C11 1:500 
BioLegend          
(San Diego, CA) 100320 
CD4 PerCP-CY5.5 
Rat 
IgG2b GK1.5 1:500 
BioLegend          
(San Diego, CA) 100434 
CD8 APC-ef780 Rat IgG2a 53-6.7 1:500 
Jomar Bioscience 
(Stepny, SA) 47-0081 
FoxP3 FITC Rat IgG2a FJK-16s 1:100 
Jomar Bioscience 
(Stepny, SA) 11-5773 
ICOS APC Hamster IgG C398.4A 1:200 
BioLegend          
(San Diego, CA) 313510 










Table 5: Compensation 
Beads 
Compensation 










Table 4: MDSC Panel 
Antibody 





IgG2b M1/70 1:100 
BioLegend          
(San Diego, CA) 101228 
CD11c AF488 Hamster IgG N418 1:100 
BioLegend          
(San Diego, CA) 117311 





CD3 PE-Cy7 Rat IgG2b 145-2C11 1:500 
BioLegend          
(San Diego, CA) 100320 
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